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ABSTRACT 
The primary focus of tissue engineering is to develop biological substitutes 
capable of restoring, maintaining, or improving native tissue function. This field 
advances an exciting array of solutions for organ repair and wound healing. In the United 
States alone over 6.5 million people are affected by chronic wounds every year, which 
account for over $25 billion of healthcare expenses. Vascularization and fast anastomosis 
with the host are essential in engineering cellular constructs that survive once implanted. 
In the last decade, there has been extensive investigation into fabrication techniques to 
create tissue replacements that are rapidly perfused post-implantation to address this 
issue. 
Three-dimensional bioprinting is a methodology used for generating 3D 
constructs of various sizes and shapes from a digital model using a layer-by-layer 
approach. These digital models can be derived from patient images, such as CT and MRI 
scans, to produce patient-specific tissue replacements. The fabrication of biomimetic 
constructs plays an essential role in the advancement of tissue engineering, and provides 
the ability to form 3D constructs that are able to recapitulate the in vivo structure and 
function of complex tissues. The Palmetto Printer, developed at the Medical University of 
South Carolina, is a custom-built multi-dispenser system that uses programmable robotic 
manufacturing methods to generate 3D heterogeneous tissue constructs. The assessment 
of the Palmetto bioprinter showed high cell viability (>95%) and significant cell 
proliferation within the printed constructs over 8 days. Therefore, this technique proves 
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its ability to generate scaffolds that allow cell growth, communication, and the formation 
of networks; each a requirement of vascularization. 
Scaffold-free tissue engineering aims to produce physiologically-relevant 3D 
multicellular constructs through the process of cellular self-assembly. We have developed 
a scaffold-free prevascular implant model with dense endothelial networks surrounded by 
extracellular matrix, similar to capillary vasculature. Upon implantation, we found that 
the host rapidly endothelialized these constructs (<6hr), and were perfused by 72 hours 
post-implantation. We have demonstrated that this technology can be modified by growth 
factors and can be scaled up into larger, more complex geometries. Furthermore, 
bioprinter fabrication could allow the creation of personalized implants.   
As an application for these fabrication techniques, we developed a novel wound 
dressing for the treatment of chronic wounds. The Smart Wound Dressing is a multi-
component device made up of three separate layers that individually address different 
facets of the chronic wound environment. This combinatorial approach will provide an 
exciting new option for the treatment of these non-healing wounds. 
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CHAPTER ONE 
 
OVERVIEW OF TISSUE ENGINEERING TECHNIQUES 
 
The primary focus of tissue engineering is to bridge the gap between organ 
shortages and transplantation needs by developing biological substitutes capable of 
restoring, maintaining, or improving native tissue function (1-2). As of 2017, in the 
United States alone, there were almost 116,000 patients on the organ transplant waiting 
list at years end, and only 16,473 recovered donors (3). The number of people on the 
waiting list has been rapidly increasing, while the number of donors and transplants has 
remained relatively constant since 1990 (Figure 1.1, 3). There is a significant 
disproportion between the supply and demand for organ transplants that must be 
improved. 
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Tissue engineering and regenerative medicine aims to alleviate this organ shortage crisis 
through the fabrication of functional tissue replacements. The typical process of tissue 
engineering starts with harvesting cells from a patient, typically through a biopsy (Figure 
1.2). The cells are then expanded in vitro, and seeded onto scaffolds, which are materials 
that support cells to grow on. The cellularized scaffolds are then cultured and allowed to 
mature before implanting the construct back into the patient (4). 
 
1.1 CONVENTIONAL TISSUE ENGINEERING TECHNIQUES 
The conventional tissue engineering approach involves the creation of acellular 
porous sacrificial scaffolds that are seeded with cells post-fabrication (5). The classical 
tissue engineering approach involves the isolation and seeding of organ-specific cells or 
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multipotent stem cells on different scaffold biomaterials (Figure 1.2; 6). Many 
techniques have been employed, such as fiber bonding, solvent casting, and melt 
molding, but proved to be minimally successful for tissue engineering applications. Fiber 
bonding methods allow fibers to be aligned in specific shapes, but they are only capable 
of producing very thin scaffolds (7). Solvent casting methods produced highly porous 
constructs, however the largest produced membrane was only 3-mm thick (8). Therefore, 
creating larger, organ-sized three-dimensional constructs is not feasible using these 
techniques. Melt molding techniques proved successful in producing three-dimensional 
scaffolds, but the high temperatures are required that biological materials cannot be 
incorporated during the production process (7). Scaffolds seeded post-fabrication are 
limited in their ability to meet the requirements of tissue engineering to produce three-
dimensional scaffolds with predefined or controllable microstructures and 
macrostructures (9). Another major issue with solid scaffold seeding technologies is the 
deficiency of vascularization and poor mechanical integrity (10-11).  
1.2 BIOMATERIALS FOR SCAFFOLD-BASED TISSUE ENGINEERING 
Biomaterials used to create the scaffolds for the development of cellular constructs 
must satisfy multiple requirements. The scaffold serves as a temporary foundation for cell 
attachment and proliferation, so it must be constructed from materials with sufficient 
mechanical properties, a timed biodegradability to non-toxic products, and a controllable 
porosity (10,12-15). Additionally, the scaffold materials should not be cytotoxic or create 
an adverse response from the host. The materials must allow for a uniform cell 
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distribution within the bioprinted constructs, so that encapsulated cells are able to 
migrate, communicate, and form intercellular connections for tissue maturation.  
1.3 ADVANCES IN BIOFABRICATION TECHNIQUES FOR ENGINEERING SOFT 
TISSUES: THREE-DIMENSIONAL BIOPRINTING 
Bioprinting has since been extended to three dimensions through the use of nontoxic, 
biodegradable, thermo-reversible or chemically crosslinked hydrogels to overcome the 
disadvantages of conventional methods (16,17). 
Types of Three-dimensional Bioprinters 
A few of the solid freeform fabrication techniques currently being employed are 
laser-assisted bioprinting and inkjet printing. Laser-assisted bioprinting techniques use a 
pulsed laser source, a target plate, and a receiving substrate to generate three-dimensional 
scaffolds (Figure 1.3; 18). However, this technique is limited due to low throughput, low 
cell viability, and can only produce limited arrangements of fabricated structures because 
only photo-crosslinkable prepolymers can be used to form a crosslinked hydrogel 
network (15,19). Inkjet printing was developed as a non-contact methodology that 
reproduces digital image data on a substrate by depositing picoliter ink droplets (Figure 
1.3; 20,21). However, inkjet printing does not produce a high-resolution construct, the 
fabricated constructs experience rapid protein denaturation, and many of the cells are 
lysed during the deposition process (22-23). Microextrusion bioprinters utilize syringe 
printer heads that deposit bioink in a drop-by-drop or layer-by-layer build-up approach. 
The biomaterials used as bioink for extrusion printing must be structurally stable or 
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include an in situ crosslinking mechanism to generate three-dimensional tissue 
constructs.  
 
Direct and Indirect Bioprinting Techniques 
Bioprinting technologies typically utilize two methods for fabricating cellular 
constructs. Indirect bioprinting involves the deposition of an acellular scaffold, shown 
here in blue, that is first created to determine the geometry of the desired construct 
(Figure 1.4; 24). This acellular mold is subsequently seeded with cells (red) to have them 
assemble in the set architectures. Once the construct has matured, the acellular blue 
scaffold is sacrificed leaving a cell-only construct. Direct bioprinting involves the 
deposition of cell-laden bioink in specific geometries to fabricate tissue constructs in 
cellularized patterns. 
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Norotte, C., et. al. investigated the possibility of creating bioprinted constructs 
with embedded vascular patterns via indirect bioprinting (Figure 1.5A-E; 17). They 
created the sacrificial scaffold using non-adherent agarose (purple rods), and were able to 
create tubes with various dimensions. The smallest tube created was 900𝜇m in diameter 
and had a wall thickness of 300𝜇m. The seeded cells (orange) fused into multicellular 
spheroids within 5 and 7 days of culture to produce a tubular construct. This group was 
able to develop tubular structures with varying diameters and wall thicknesses, indicating 
an ability to tailor this technology to specific vascular constructs. 
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The creation of tubular cell constructs is an exciting achievement, but there were 
many deficiencies observed with these constructs. The time to create larger constructs 
was very time consuming as fusion of spheroids can take up to a week and may result in 
non-uniform tubular surfaces. Additionally, the formed constructs indicated positive for 
apoptotic cells, likely due to the limited diffusion of oxygen and nutrients to these 
constructs. 
1.4 SCAFFOLD-FREE TISSUE ENGINEERING 
Scaffold-free tissue engineering aims to produce physiologically-relevant three-
dimensional multicellular constructs without the use of a scaffold. These methods have 
been developed as ways to avoid the issues associated with scaffold materials, such as 
toxicity of by-products, uncontrolled mechanical properties, and others, as well as to 
develop more physiologically-relevant constructs that rely on the mechanisms driving 
tissue development in vivo.  
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Generation of Multicellular Spheroids 
The creation of multicellular spheroids relies on the use non-adherent molds, which 
means that the cells are unable to interact with or adhere to the material used (Figure 
1.7). Cells are expanded on cell culture dishes, and then harvested using enzymatic 
digestion, typically trypsinization (Figure 1.7B). The suspended cells, shown in blue, are 
then seeded into the non-adherent mold, and cultured. Cellular constructs are formed in 
the dimensions of the non-adherent mold with time in culture.  
 
During the culture period, the cells undergo the process of cellular self-assembly, 
which relies on the inherent capability of cells to migrate and for intercellular 
connections (25). Adherent cells depend on the formation of these intercellular as well as 
cell-matrix connections for survival. When adherent cells are placed in an environment 
that lacks a surface for adhesion, the cells will aggregate and undergo the process of self-
assembly. During this process, suspended cells form three-dimensional multi-cellular 
spheroids. The produced multicellular spheroids have similar architectural and functional 
characteristics of native tissues.  
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Cell Sheet Engineering 
Another emerging technique for generating scaffold-free constructs, is cell sheet 
engineering. Harvesting cells via enzymatic digestion, trypsinization, cell-cell junctional 
proteins and deposited extracellular matrix are disrupted and degraded for cell recovery 
(Figure 1.7B). To overcome this limitation Yang, J., et. al. developed temperature-
responsive cell culture dishes to create scaffold-free cellular sheets (26). The 
temperature-responsive cell culture dish is created by covalently attaching a thermo-
responsive polymer, poly(N-isopropylacrylamide) (PI-PAAm). During normal culture 
conditions, 37℃ and 5%	CO#, the surface is hydrophobic and allows cell attachment, 
migration, and proliferation. Once a confluent monolayer has been established on the 
culture plate, the temperature is reduced to 32℃, or the PI-PAAm lower critical solution 
temperature, which causes the dish surface to become hydrophilic and swell (Figure 
1.7C). A hydrated layer forms between the cells and the culture plate, which permits their 
spontaneous detachment without the need for enzymatic digestion. This retains essential 
cell surface proteins like ion channels, growth factor receptors, and cell-cell junctional 
proteins within the cell sheet constructs. Additionally, the deposited extracellular matrix 
is harvested with the cellular sheets, allowing for the reconstruction of multiple tissues 
and organs using this technique.  
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1.5 LIMITATIONS IN TISSUE ENGINEERING 
The field of tissue engineering advances an exciting array of solutions for organ 
repair and wound healing. However, to realize this potential, several hurdles must be 
overcome. Vascularization is arguably the most important practical limitation in tissue 
engineering, imposing both dimensional and time constraints on the technology. 
Vascularization and fast anastomosis with the host are essential in engineering cellular 
constructs that survive once implanted, as well as tissue maintenance and regeneration. 
Endothelial cell migration and physiological growth of new blood vessels in vivo has 
been reported to occur at ~5 um/hour due to the availability of oxygen, which is limited 
to a diffusion distance of 150 − 200µm from a supplying blood vessel (27-28).   
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With the clinical need being for larger engineered tissues, a major focus in the tissue 
engineering field has been on designing constructs with pre-existing vascular 
architectures (Figure 1.5) or, more recently, prevascularized constructs. This dissertation 
focuses on the integration of scaffold-based and scaffold-free techniques to develop novel 
technologies for engineered tissue replacements and wound dressings that address the 
limitations described in this chapter. 
1.6 REFERENCES 
 
1. Smith, C.M., Christian, J.J., Warren, W.L., & Williams, S.K. Characterizing 
Environmental Factors that Impact Viability of Tissue-Engineered Constructs 
Fabricated by a Direct-Write Bioassembly Tool. Tissue Engineering. 13 (2), 373-383, 
(2007). 
2. Ozbolat, I. and Yu, Y. Bioprinting Towards Organ Fabrication: Challenges and Future 
Trends. IEEE Trans Biomed Eng. 60 (3), 691-699, (2012). 
3. Derakhshanfar, S., Mbeleck, R., Xu, K., Zhang, X., Zhong, W., and Xing, M. 3D 
bioprinting for biomedical devices and tissue engineering: a review of recent trends 
and advances. Bioactive Materials. 3:144-156, (2018).  
4. Abou Neel, E.A., Chrzanowski, W., Salih, V., et. al. Tissue Engineering in Dentistry. 
Journal of Dentistry 42(8): 915-928, (2014).   
5. Yeong, W.Y., Chua, C.K., Leong, K.F., & Chandrasekaran, M. Rapid Prototyping in 
Tissue Engineering: Challenges and Potential. Trends Biotechnol. 22 (12), 643-652, 
(2004). 
6. Laschke, M.W. and Menger, M.D. Vascularization in Tissue Engineering: 
angiogenesis versus inosculation. Eur Surg Res. 48(2):85-92, (2012). 
7. Lu, L. and Mikos, A.G. The Importance of New Processing Techniques in Tissue 
Engineering. MRS Bull. 21(11), 28-32, (1996). 
8. Wake, M.C., Gupta, P.K., Mikos, A.G. Fabrication of pliable biodegradable polymer 
foams to engineer soft tissues. Cell Transplant. 5(4), 465–473, (1996). 
9. Yang, S., Leong, K.F., Du, Z., & Chua, C.K. The Design of Scaffolds for Use in 
Tissue Engineering. Part II. Rapid Prototyping Techniques. Tissue Engineering. 8 (1), 
1-11, (2002). 
10. Sachlos, E. & Czernuszka, J.T. Making Tissue Engineering Scaffolds Work. Review 
on the Application of Solid Freeform Fabrication Technology to the Production of 
Tissue Engineering Scaffolds. European Cells and Materials. 5, 29-40 (2003). 
11. Mironov, V., Visconti, R.P., Kasyanov, V., Forgacs, G., Drake, C.J., & Markwald, 
R.R. Organ Printing: Tissue Spheroids as Building Blocks. Biomaterials. 30 (12), 
2164-2174, (2009). 
 12 
12. Landers, R., Pfister, A., Hubner, U., John, H., Schmelzeisen, R., and Mulhaupt, R. 
Fabrication of Soft Tissue Engineering Scaffolds by means of Rapid Prototyping 
Techniques. Journal of Materials Science. 37 (15), 3107-3116, (2002). 
13. Murphy, S.V., Skardal, A., and Atala A. Evaluation of Hydrogels for Bio-Printing 
Applications. Journal of Biomedical Materials Research Part A. 101A (1), 272-284, 
(2013). 
14. Burg, K.J.L. & Boland, T. Minimally Invasive Tissue Engineering Composites and 
Cell Printing. IEEE Eng Med Biol Mag. 22 (5), 84-91, (2003). 
15. Billiet, T., Vandenhaute, M., Schelfhout, J., Van Vlierberghe, S., & Dubruel, P. A 
Review of Trends and Limitations in Hydrogel-Rapid Prototyping for Tissue 
Engineering. Biomaterials. 33 (26), 6020-6041, (2012). 
16. Gruene, M., et al. Laser Printing of Three-Dimensional Multicellular Arrays for 
Studies of Cell-Cell and Cell-Environment Interactions. Tissue Eng. 17 (10), 973-982, 
(2011). 
17. Norotte, C., Marga, F.S., Niklason, L.E., & Forgacs, G. Scaffold-free Vascular Tissue 
Engineering Using Bioprinting. Biomaterials. 30 (30), 5910-5917, (2009). 
18. Devillard, R., et al. Cell Patterning by Laser-Assisted Bioprinting. Methods Cell Biol. 
119: 159-174, (2014). 
19. Ferris, C.J., Gilmore, K.G., Wallace, G.G., & Panhuis, M. Biofabrication: An 
Overview of the Approaches Used for Printing of Living Cells. Appl. Microbiol. 
Biotechnol. 97 (10), 4243-4258, (2013). 
20. Binder, K.W., Allen, A.J., Yoo, J.J, & Atala, A. Drop-on-Demand Inkjet Bioprinting: 
a Primer. Gene Ther Reg. 6 (1), 33-, (2011). 
21. Murphy, S.V. & Atala, A. 3D Bioprinting of Tissues and Organs. Nat Biotech. 32 (8), 
773-785, (2014). 
22. Xu, T., et al. Viability and Electrophysiology of Neural Cell Structures Generated by 
the Inkjet Printing Method. Biomaterials. 27 (19), 3580-3588, (2006). 
23. Calvert, P. Inkjet Printing for Materials and Devices. Chem Mater. 13 (10), 3299-
3305, (2001). 
24. Jia, J., et al. Engineering Alginate as Bioink for Bioprinting. Acta Biomaterialia. 10 
(10), 4323-4331, (2014). 
25. Czajka, C. and Drake, C.J. Self-assembly of prevascular tissues from endothelial and 
fibroblast cells under scaffold-free, non-adherent conditions. Tissue Eng Part A. 21(1-
2):277-287, (2015). 
26. Yang, J., Yamato, M., et. al. Cell sheet engineering: recreating tissues without 
biodegradable scaffolds. Biomaterials 26:6415-6422, (2005).  
27. Grimes, D.R., Kelly, C., Bloch, K., and Partridge, M. A Method for Estimating the 
Oxygen Consumption Rate in Multicellular Tumour Spheroids. J. Royal Society 
Interface 11(92): 1-11, (2014). 
28. Matthias, W., Laschke, M.W., Vollmar, B., Menger, M.D. Inosculation: Connecting 
the Life-Sustaining Pipelines. Tiss Eng: Part B 15(4):455-462, (2009). 
 
 
 13 
CHAPTER TWO 
BIOFABRICATION AND BIOMATERIALS 
Organ transplantation has been limited by two major factors: a critical shortage in 
donors and a high risk of graft rejection (58). With over 120,000 patients on the organ 
waiting list as of 2017, transplantation is not a feasible option for many of these people 
(54). Tissue engineering utilizes the principles of biology and engineering to develop 
functional substitutes that serve to maintain, restore, or enhance native tissues and organs 
(1). The traditional tissue engineering techniques involve the creation of a solid, porous 
scaffold that is seeded with cells post-fabrication. The scaffold is designed to try to 
encourage cells to form the desired tissue by the incorporation of specific cell types, 
growth factors, or other signaling molecules (55).  However, these techniques have been 
met with limited success due to the lack of organization and hierarchy within the 
constructs that is typically seen in native tissues. Additionally, under these conditions the 
cells are unable to grow in favored three-dimensional orientations, which is often 
accompanied by loss of tissue-specific function (3-5).  
The capability of generating three-dimensional biomimetic constructs on demand 
would facilitate scientific and technological advances in tissue engineering as well as in 
cell-based sensors, drug/toxicity screening, tissue or tumor models, and other areas (2). 
This has led to the direct fabrication of scaffolds with a complex, anatomically correct 
external geometry, and precise control over the internal geometry (9). Three-dimensional 
bioprinting is a methodology used for generating three-dimensional constructs of various 
sizes and shapes from a digital model using a layer-by-layer approach (34). The 
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fabrication of three-dimensional biomimetic constructs plays an essential role in the 
advancement of tissue engineering, and the bioprinting process restores the ability to 
form three-dimensional constructs that are able to recapitulate the in vivo-like structure 
and function of complex tissues. 
2.1 ADVANCED ADDITIVE MANUFACTURING BIOPRINTING 
As an additive manufacturing technique, three-dimensional bioprinting involves 
the deposition of either cell-laden biomaterials, or acellular biomaterials that are seeded 
post-fabrication (54).  Extrusion bioprinters have been developed as an expansion of 
inkjet printing in order to deposit more viscous materials with higher local cell densities 
(54). The versatility of these machines permits the deposition of almost all types of 
hydrogel pre-polymer solutions with varying ranges of viscosity and cell aggregates (53). 
These bioprinters are also able to deposit concurrent lines of cell-laden materials as 
opposed to independent droplets in traditional techniques.  
The typical workflow of extrusion bioprinting of cell-laden materials is shown in 
Figure 2.1, and involves the isolation and expansion of human cells in vitro, mixing these 
cells into a printable material, and finally, depositing cell-laden scaffolds in a layer-by-
layer fashion (53; Figure 2.1). In these systems cells, proteins, growth factors, and others 
can be integrated into the matrix materials during the fabrication process and 
concurrently deposited using computer-controlled actuators to generate three-dimensional 
cell-laden scaffolds that closely mimic the microarchitecture of native tissue (12,28,45). 
The produced scaffolds can be used as therapeutic devices themselves (i.e. implant the 
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generated constructs), as a testing platform for drug screening and discovery, as well as 
an in vitro model for disease (53).  
 
Bioprinting typically utilizes two methods for creating three-dimensional 
constructs: direct and indirect printing. Direct bioprinting techniques have cells, as well 
as other factors (i.e. growth factors, peptides, etc.), loaded in a cytocompatible bioink that 
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are deposited together to generate cellularized scaffolds. Constructs generated with this 
technique rely on a fast gelation/crosslinking in order to sustain the stable structure (44; 
Figure 2.2). Indirect printing methods generate an acellular negative structure that serves 
as a scaffold for cell-seeding post-fabrication (44; Figure 2.2).  
 
2.2 BIOMATERIALS FOR EXTRUSION-BASED, DIRECT-WRITE BIOPRINTING 
Human tissue biology is heavily regulated by specific interactions and cross-talk 
between different resident cell populations. The three-dimensional organization of tissue-
engineered constructs is a fundamental component of the fabrication method because the 
produced constructs must closely mimic the highly organized interaction of cells and 
extracellular matrix in native tissue. The materials in which the cells are embedded 
directly influences the mechanical and biological properties of the produced scaffold, as 
well as subsequent cell behaviors within that scaffold. Therefore, the two most critical 
factors for bioprinting functional tissue replacements are the biomaterials used to create 
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scaffolds and the cell types incorporated within those scaffolds in order to adequately 
recapitulate these complex microenvironments in vitro (53,54).  
Each technique for bioprinting has different requirements for the materials used to 
create scaffolds, as discussed in chapter 1. Bioinks are typically comprised of cell-laden 
pre-polymer solutions (53). The ideal bioink must satisfy specific material and biological 
requirements because it serves as a temporary foundation of cell attachment and 
proliferation. Important material properties include tunable mechanical properties, 
printability, crosslinking mechanism, biocompatibility, and controlled degradation into 
non-toxic by-products (4,6-9,47).  
Extrusion-based bioprinters used for printing cell-laden materials are able to 
incorporate higher cell densities than other techniques, and are able to print materials 
with viscosities ranging from 30 − 60 × 10$mPa (54). Cell-laden bioprinting requires 
the material used for encapsulation has a high-water content and adequate porosity for 
cells to receive nutrients and oxygen from the environment, and remove waste to sustain 
viability within the scaffold (54). Hydrogels, both natural and synthetic, have been 
frequently employed in bioprinting due to their structural similarity to the 
macromolecular-based components of the body, and their tissue-mimetic properties (52). 
These hydrophilic materials are able to absorb large amounts of water within their three-
dimensional networks, and retain this water in their swollen state (56).  
The mechanical properties of hydrogels are significantly important for tissue 
engineering applications where the gel must create and maintain a space for cell 
infiltration and tissue development (52). The mechanical properties of the scaffolds post-
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polymerization must be adequate to sustain a suitable environment for cell attachment, 
proliferation, and differentiation (53). These properties include shear stress, strain, 
compressive modulus, and the mass swelling ratio (7). 
Printability refers to the interaction between the deposited bioink and the printing 
substrate that allows for the formation of high-quality, geometrically accurate constructs. 
This property is related to the surface tension between the bioink and substrate, which 
can be measured by the contact angles between the two materials, as well as the 
resolution of the bioprinter (53). The deposited pre-polymeric bioink solution should 
have a large contact angle with the substrate, which is produced when the bioink solution 
maintains tension in the vertical direction (53). Bioprinters in the literature have reported 
resolutions ranging from 10 − 10,000𝜇m (54). The wide range of resolutions is due to 
the fact that many labs are developing novel in-house bioprinter setups for applications 
that have specific requirements within this range. In general, bioprinters have a resolution 
on the micron-scale, which is relevant on a cellular level (54). The crosslinking 
mechanism of the bioink also has a large effect on its printability. In order to deposit cell-
laden solutions, the materials must be polymerized post-printing. Therefore, the 
mechanism for gelation must be gentle on cells and not impact cell viability. There are 
three dominant methods of crosslinking frequently used for bioprinting applications: 1) 
photo-crosslinking, 2) physical crosslinking, and 3) chemical crosslinking (53). Photo-
crosslinking utilizes the polymerization of light-sensitive polymers, however, many of 
these techniques require the use of ultraviolet (UV) light, which can be toxic to 
encapsulated cells, as well as degrade the matrix in which the cells are embedded (54). 
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Chemical crosslinking leads to the formation of permanent junctions, while 
transient/reversible three-dimensional polymer networks are formed via physical 
crosslinking, such as thermal crosslinking techniques (56). 
Biocompatibility is determined by how the biomaterial performs with the host 
response in a specific situation. In vitro, it is required that the material is not harmful to 
cell survival, proliferation, and provides proper binding sites for cells embedded within it 
(53). In vivo, it is additionally required that the biomaterial can be degraded or 
incorporated into the native extracellular matrix without producing toxic by-products or 
resulting in destructive interactions with host cells (53). Once implanted, biodegradable 
hydrogels can be broken down into lower-molecular weight, water-soluble fragments that 
can be resorbed or excreted by the body once the function of the gel has been completed 
(52). This makes these materials promising choices for releasing drugs or other factors in 
a clinically-relevant timeline. 
2.3 MODIFIED ALGINATE AS A BIOACTIVE SCAFFOLD 
More recently, the engineering of “smart”, or bio-functional, and composite 
materials have evolved due to the limitations of using a single material for various 
bioprinting applications (53). Native alginate, which is arguably the most frequently used 
bioink in bioprinting applications due to its biocompatibility and gentle gelation 
mechanism (30,59). Alginate is a natural polysaccharide derived from seaweed, and is 
comprised of alternating chains of polyguluronate (G) and polymannuronate (M) (Figure 
2., 60). The mechanical properties, pore size, and crosslinking density of the alginate 
polymers can be controlled by varying the M:G monomers ratio (60). It has been shown 
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that alginates containing a high fraction of polyguluronate blocks produces gels with 
superior strength compared to those with high amounts of polymannuronate (60). 
Alginate is polymerized in the presence of divalent cations, like calcium, that ionically 
crosslink the carboxylate groups in the polyguluronate blocks of the copolymer structure 
(30,60). However this material is bioinert, i.e. lacks cell-binding sites, contains minimal 
cell-activating properties, and only gets minimally degraded in vivo (54). The in vivo 
degradation of native alginate is caused by the loss of divalent cations in an uncontrolled 
manner, and results in the release of both low- and high-molecular weight strands. The 
resultant high-molecular weight strands are not easily broken down and may take long 
periods of time to be cleared from the body, if at all.  
 
To expand on this material for regenerative applications, alginates functionalized 
with RGD-binding sites have been frequently used as bioink to provide a matrix scaffold 
that will direct a specific 3D cell growth (37). Scaffolds made using RGD-conjugated 
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alginate were shown to be capable of forming robust cell-compatible hydrogels in 
physiological conditions (7,14,17,44). 
 
Additionally, chemically modifying the alginate through oxidation has been 
demonstrated in the literature to produce scaffolds with controllable degradation rates 
(37). Partial oxidation using sodium periodate alters the conformation of the uronate 
residues into an open-chain adduct, which are vulnerable to hydrolysis (Figure 2.5, 61).  
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By changing the polymeric chain to an “open” state the pore size of the resultant 
hydrogel is less dense as well as the stiffness, which has been reported to enhance cell 
viability in implanted constructs (37, 61). For example, Jia, et. al. showed that varying the 
degree of oxidation and concentration of the alginate used effected the viability human 
Adipose-derived stem cells in bioprinted constructs (Figure 2.3; 37). High viabilities 
(>90%) were associated with alginate bioinks with medium viscosities (~400mm#s%&), 
while low viabilities were observed in high viscosity bioinks (~3,000mm#s%&). The 
differences seen in cell viability between the materials was attributed to the denser 
polymeric environment associated with high viscosity alginates, which diminished 
nutrient transport to the cells embedded in these constructs (37). Therefore, when using 
modified alginate as a vehicle for cell encapsulation and transplantation, it is essential to 
 23 
determine the appropriate environment required for the specific application and to modify 
the materials to meet those demands.   
 
Another avenue for material modification is the combination of multiple materials 
to produce a heterogeneous scaffold. Through the combination of different hydrogels, the 
synthesized scaffold’s properties are modifiable to meet distinct application requirements. 
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To further expand alginate as a useful material for regenerative tissue engineering 
applications it could be combined with collagen to provide structural and cell-adhesive 
properties. Collagen is the most abundant protein in mammalian tissues and is the main 
component of natural extracellular matrix (46). It inherently contains RGD cell-binding 
sites, and provides structural support and mechanical strength to tissues in vivo (46,57). 
Additionally, collagen is known to permit cell adhesion, chemotaxis, and migration, 
making it a good candidate for bioprinting applications. We have developed 
collagen/alginate blend hydrogels that, in collaboration with other labs at the Medical 
University of South Carolina, have been explored for applications including timed drug 
release of vancomycin for surgical implant sites (provisional patent submitted), as well as 
for the attachment, migration, and subsequent release of regulatory T-cells for in vivo 
applications (provisional patent submitted). The incorporation of additional materials or 
chemical modifications could expand the use of this material to a multitude of different 
applications, such as wound healing and fabricating soft tissue replacements. 
2.4 MIMICKING THE COMPLEX IN VIVO MICROENVIRONMENT 
Every tissue in the body is composed of multiple cells types positioned relative to 
each other in specific, complex orientations and patterns. To replicate this on a cellular 
level in vitro, the hydrogels that constitute the bioink can be heterogeneous, i.e. 
consisting of multiple cell types and/or materials, or homogeneous, depending on the 
tissue being replicated. Additive manufacturing systems deposit these multicellular 
building blocks, or the bioink, drop-by-drop or layer-by-layer via disposable syringes and 
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tips onto a computer-controlled stage capable of moving in the x, y, and z directions. 
Through computer software, the architecture of printed scaffolds can be easily 
manipulated to mimic tissue-specific patterns depending on the requirements of the 
application. Unlike conventional techniques, three-dimensional medical technologies (i.e. 
magnetic resonance imaging, computer tomography) can be incorporated into the 
designs, which enables the possibility of generating patient-specific constructs (10).  
2.5 THE PALMETTO BIOPRINTER 
The Palmetto Printer is a custom built three-dimensional multi-dispenser system 
that uses programmable robotic manufacturing methods to generate three-dimensional 
heterogeneous tissue constructs (Figure 2.4). It allows the use of a plurality of materials 
in unique combinations to produce heterogeneous structures. The initialization of the 
bioprinter is one of the most important steps in bioprinting because it allows you to set a 
variety of parameters to optimize the printability of the bioprinted constructs.  
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The bioprinter comprises a batch type process with startup, operation and 
shutdown sequences controlled by a programmable logic controller (PLC), which the user 
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operates through an interactive touch screen control panel (Figure 2.4, A). To prevent 
contamination of biological materials the bioprinter is enclosed in a positively-pressured 
poly(methyl methacrylate) (PMMA) chamber with a high-efficiency particulate 
arrestance (HEPA)-filtered air circulation system (Figure 2.4, B,C). The interior of the 
printer can be sterilized using the built-in ultraviolet light sources (Figure 2.4, D). The 
central component of the bioprinter is a fully programmable positioning robot that can 
reproducibly place a dispenser tip with an accuracy of 10 micrometers (Figure 2.4, E). 
There are three dispensers, which are able to deposit volumes as small as 230 nanoliters 
using a rotary screw (Figure 2.4, F). They are independently programmable using 
separate computers that govern printing parameters for each dispenser (Figure 2.4, G). 
Rotary-screw dispensing utilizes the rotation of a motor-driven screw to move bioink 
down a syringe and out of the syringe tip. These dispensers are mounted onto a 
pneumatically controlled Tool Nest (Figure 2.5, A, B), allowing the robot to switch 
dispenser mounted onto the Z-axis robotic arm under programmed control (Figure 2.4, 
H).  
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The XYZ robot receives printing instructions from a computer running design 
software (Figure 2.4, I). Each program contains dispensing locations, calibration 
routines, and dispenser-changing protocols. The design of generated constructs primarily 
consists of the XYZ coordinates where each dispenser will deposit material. The 
bioprinter comprises two optical light sensors (Figure 2.5, C) that determine the XYZ 
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coordinates of the syringe tip end. These sensors send coordinate information to the 
robot, which uses these to calculate positions of the dispenser tip ends. There is an 
additional displacement laser (Figure 2.4, D) that projects a 633 nm diode red laser beam 
of spot size 30 x 100 micrometers to measure distance with an accuracy of 0.1 
micrometers. When the beam is highly focused the robot determines the Z distance of the 
printing surface. This measurement, and the optical light sensors measurement of the tip 
end in Z, allows calculation of accurate Z coordinates used to place the dispenser tip in 
relation to the printing surface. The dispenser tips move laterally and vertically through 
the X-axis oriented optical light sensor to find the Y and Z centers, and laterally through 
a Y-axis sensor to find the center of the X-axis. The printing surface is mapped using the 
formula for a flat plane in xyz space: ax + by +cz = d to determine where the surface is 
relative to the position of the dispensing tip end. The printer stage (Figure 2.4, J) holds a 
sample Petri dish up to 80 mm in diameter and uses a recirculating water bath to maintain 
the set temperature (Figure 2.4, K). Stage temperature can be set within a range of -20 
and remains stable within a range of -20-100 degrees Celsius and remains stable within 
0.5 degrees Celsius. There is a USB camera mounted onto the robot Z-arm to provide a 
magnified view of the dispensing tip during the printing process (Figure 2.4, L). There is 
a second camera mounted towards the top of the chamber interior that provides a 
complete view of the bioprinter during the printing process (Figure 2.4, L).  
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A computer-aided design drawing software determines the deposition pattern and 
permits the user to generate incrementally spaced droplets and complex structures 
(Figure 2.6). Three- dimensional pathways can be manually coded into the printer-
compatible design software or imported from a separate computer-aided design drawing 
software (Figure 2.7, Table 2.1). The printer-compatible software allows variations of 
printing parameters such as the deposition method (single droplet deposition or 
continuous pathway deposition), three-dimensional geometry of the pathways, deposition 
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rate, distance between the syringe tip end and substrate printing surface, the amount of 
time to deposit an individual drop, and the height and speed the syringe is lifted between 
deposition of the drops. Each program contains XYZ dispensing locations, tip calibration 
routines, and dispenser-changing protocols to provide a sterile environment, without 
operator intervention, during printing. The programmable logic controller (PLC) of the 
robot receives instructions from the computer running the design software and controls 
the timing of events from the external controllers (e.g. the dispensers). To do this, the 
PLC uses a looping mechanism to control the dispensers, robotic positioning device, and 
environmental factors.  
In this study we aimed to characterize a variety of materials that could function as 
vehicles for the transplantation of cell-laden constructs by analyzing different material 
properties and cell behaviors within these biomaterials. We hypothesize that the Palmetto 
Printer, developed at MUSC, is capable of depositing viable cell-laden structures in 
biomimetic geometries that accurately replicate the in vivo environment with respect to 
mechanical properties and cellular functions. 
2.6 MATERIALS AND METHODS 
Collagen Extraction 
Collagen was extracted from the hide of an 18-month-old bovine steer following the 
methods of Yost, et al. (50). The superficial epidermis, including the hair and follicle pits, 
was first removed using a scalpel. The hide was then cut into 4 × 6	cm strips and was 
washed three times in deionized water for 1 hour per wash, with the second wash 
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including 0.2%	NaHC)'. The leftover follicles and non-collagenous proteins were 
removed by washing in a solution of 0.6%	NaHCO', 2%	Ca(OH)#, and  4.3%	NaHS	for 
30 minutes at 20℃. The hides were then washed three times in deionized water and 
soaked in  2%	Ca(OH)#	at 4℃ overnight. The fat and epidermis remaining after the 
overnight wash was trimmed, and the strips were placed in a 2M sodium chloride (NaCl) 
solution and neutralized with hydrochloric acid (HCl) to pH 6.8-7.0. The hide strips were 
then washed three times in deionized water, and cut into smaller 0.5 × 2	cm pieces and 
placed into a solution of 0.5Nacetic acid, containing pepsin (1:100 based on hide weight), 
and incubated overnight at 4℃. The strips were then mixed with ice and emulsified into a 
gel dispersion using a Kitchen-Aid food processor (model FP500WH; Kitchen-Aid, St. 
Joseph, MD). The suspension was centrifuged at 9950× g for 35 minutes, resuspended 
in deionized water, and neutralized to pH 7.2 with NaOH. The collagen suspension was 
then dialyzed versus phosphate-buffered saline overnight, and then versus deionized 
water for three changes over 24 hours. The resulting collagen gel was centrifuged at 9950 × g  for 35 minutes to remove excess water, and the collagen concentration was 
adjusted to 25mg mLC   by adding deionized water. The collagen was then aliquoted into 
50mL tubes and stored at  −20℃ until ready for use.  
Synthesis of Collagen Bioinks 
When ready for use, the collagen was thawed, diluted to the appropriate concentration 
using deionized water, and the pH was adjusted to pH 2.5-3.0 with concentrated HCl. 
Once acidified, the collagen was diluted to the desired concentration using cold, 4℃, 
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deionized water. The pH was then checked again, and if it was not pH ~3.0, the collagen 
was again acidified using concentrated HCl.  
Synthesis of Alginate Bioinks 
 
Sodium Alginates, Protanal LF 20/40 and Protanal LF 10/60 FT, were generously 
provided by FMC BioPolymer (Philadelphia, PA). The alginate powder was sterilized via 
gamma irradiation (at 1200cGy for X minutes) followed by UV exposure for two hours in 
a cell culture hood. To make 50 mL of 5% (weight-to-total volume) alginate bioink, 2.5 
grams of sodium alginate was mixed with 50 mL sterile ddH#O. It was then kept in the 
cell culture hood until use. 
Oxidation of Alginate Hydrogels 
Sodium alginate was oxidized following the method for partially oxidized alginate by 
Bouhadir, et. al. (30). To make a 5% oxidized alginate solution 1 gram of sodium alginate 
was dissolved in 100mL of distilled water. An aqueous solution of sodium periodate 
(0.25M, 0.25 mmol), the oxidizing reagent, was added to produce a 5% oxidation 
solution. The solution was stirred for 19 hours at room temperature. Finally, at the 24 
hour time point, 40 mL of ethylene glycol was added to the solution to end the reaction. 
2.5 grams of sodium chloride was added to the solution, as well as an excess amount of 
ethyl alcohol (2:1) in order to precipitate the oxidized alginate. The solution was 
centrifuged at 1000xg to collect the precipitates, which were then re-dissolved in distilled 
water. The ethanol wash was then repeated. The pellets were freeze-dried and stored at  −20℃	until ready for use. The degree of oxidation was determined by measuring the 
 35 
percentage of sodium periodate consumed before being terminated by the ethylene 
glycol. This was accomplished by preparing a potassium iodide solution (20% w/v, pH 
7.0 sodium phosphate buffer) and a thyodene solution (10% w/v, pH 7.0 sodium 
phosphate buffer). The two solutions were mixed with the oxidized alginate at room 
temperature. The reacted alginate and sodium periodate solution were gradually dropped 
into the mixed potassium iodide and thyodene solutions. The absorbance of the mixture 
was measured spectrophotometrically at 426nm. When the maximum absorbance was 
reached, the used volume of the alginate and sodium periodate solution was recorded as V&. The reaction is IO(% + 2I% = I# + IO'%, and the amount of unreacted sodium periodate 
was calculated using the following formula: 20%	 I)*J × 10mL × 100!+,! . The amount of 
unreacted sodium periodate was subtracted from the original concentration to determine 
the amount of sodium periodate consumed during the reaction and the degree of 
oxidation of the alginate. 
RGD-conjugation onto Alginate Hydrogels 
Ligands with an exposed arginine-glycine-aspartate sequence (G(RGDSP peptide) were 
conjugated onto the previously oxidized alginate by following the RGD-Alginate 
conjugation method described by Rowley, et. al. in order to promote cell attachment and 
spreading (31). Aqueous carbodiimide chemistry with G(RGDSP was used to conjugate 
the RGD peptide onto the alginate polymer. 1 g of 5% oxidized alginate was dissolved in 
a 0.1 M 2-(N-morpholino) ethanesulfonic acid (MES) buffer, pH = 4. 1-ethyl-
(dimethylaminopropyl) carbodiimide (EDC, 0.54 mmol) and N-Hydroxysuccinimide 
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(NHS, 0.27 mmol) were added at 2:1 ratio to form amide intermediate. 0.28 mmol G(RGDSP peptide was added, which couples to the backbone of the alginate polymer via 
the terminal amine, and stirred overnight. The coupling reaction was terminated by 
adding 2.5 g sodium chloride to the solution. An excess amount of ethyl alcohol (2:1) 
was added to precipitate the RGD-conjugated oxidized alginate. The mixture was 
centrifuged at 4,000xg for five minutes to collect the precipitates. The supernatant was 
aspirated in the cell culture hood, and the precipitates were re-dissolved in distilled water. 
The ethanol wash was then repeated. The samples were then freeze-dried and stored at −20℃ for later use. 
RGD Peptide Conjugation Analysis 
The success of RGD peptide conjugation on the alginate was determined by comparing 
RGD-alginate and non-conjugated alginate. This was done by imaging the printed 
constructs using (4’, 6-Diamidino-2-Phenylindole, Dihydrochloride) (DAPI) and 
phalloidin stains. The phalloidin working solution was created by diluting 5𝜇L of the 
methanolic stock solution with 200𝜇L of DPBS++. A 300𝜇M stock solution of the DAPI 
stain was made following the equation: 
-.&-/-01 +2'/-.'1 !342 = 3 × 10%(M = 0.0003M =0.300mM = 300µM. The DAPI working solution was made by diluting the stock 
solution 1:100 in DPBS++ to obtain 3𝜇M solution. The samples were completely 
submerged in 37℃, 4% paraformaldehyde, and incubated for one hour at room 
temperature. The samples were then washed three times with DPBS++, and the solution 
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was allowed to sit for 5 minutes each wash. The gel samples were then transferred from 
the well to a glass slide, and the gel was flipped over in the process. The samples were 
then immersed in 0.1% Triton X-100 ( -.&1&--!+) in DPBS++ for ten minutes. Each sample 
was washed three times in DPBS++ for five minutes per wash. The bioprinted constructs 
were stained with phalloidin by immersing them in the working solution in the dark for 
four hours. The phalloidin stain was removed and the samples were washed three times. 
The first wash was fast (~45 seconds), while the latter washes were for 5 minutes each. 
The bioprinted constructs were stained with DAPI by immersing them in the DAPI 
working solution in the dark for thirty minutes. The samples were washed three times for 
5 minutes per wash. The samples were imaged on a confocal microscope system and 
analyzed. 
Preparation of 𝑪𝒂𝟐6-Contatining Gelatin Substrate for 3-D bioprinting of Alginate 
Hydrogels 
 
The calcium substrate was prepared following the methods by Pataky et al in order to 
avoid reduced viability associated with high concentrations of Ca#6 (11).  Briefly, 
calcium chloride dehydrate, sodium chloride (0.9 wt.%), and porcine gelatin (2 wt.%) 
were combined in distilled water and boiled for 2 minutes to form a 100mM CaCl# 
gelatin solution.  To increase the opacity of the surface, titanium dioxide (0.3 wt.%) was 
added to the gelatin solution and stirred for 10 minutes. 5 ml of gelatin/TiO# mixture was 
put into standard petri dishes and left to gel in the 4℃ refrigerator overnight to be used 
within 3 days. 
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Cell Culture 
Human adipose tissue stromal cells (hADSC’s) were cultured in 75 cm treated cell 
culture flasks (T75 flasks), covered with 15 mL low glucose DMEM with 10% fetal 
bovine serum and 1% penicillin-streptomycin, 1% glutamine, and 1% antimycin. Media 
was changed every two days until the cells reached confluence (80-90%). Once 
confluent, the cells were suspended via trypsin enzyme digestion method.  
Normal Human Dermal Fibroblasts (NHDF) were cultured in 175-cm treated cell culture 
flasks (T175), covered with 25 mL of Fibroblast Growth Medium-2 (FGM-2, Lonza). 
The media was changed every two days until the cells reached ~85% confluence. Once 
confluent, the cells were suspending using trypsin enzyme digestion. 
Human Adipose Microvascular Endothelial Cells (HAMEC) were cultured in 75 cm 
treated cell culture flasks covered with 15 mL of Endothelial Growth Medium-2 (EGM-2, 
Lonza). Media was changed every two days until the cells reached 80% confluence. Once 
confluent, cells were suspended via trypsin enzyme digestion method. 
Bioprinter Setup 
First, the bioprinter was turned on, as well as each of the dispenser computers and the 
recirculating water bath. The recirculating water bath temperature was set to 4℃ in order 
to maintain the gelatin substrate solution in a solid state. The printing parameters were 
manually set for each dispenser on the correlating dispenser computer, including the 
dispense volume, back-off steps, and the dispense rate. The JR-C points design software 
was opened, and additional printing parameters were set, including the distance between 
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the tip end and the substrate surface, the distance the syringe is lifted between 
depositions, and the amount of time per deposition. The program was saved and then sent 
to the robot. The gelatin/TiO#-containing Petri dish was placed on the 4℃ printer stage, 
and the chamber door was closed and locked. The PLC was used to initialize the 
ultraviolet light sources for 90 seconds in order to sterilize the chamber. Once the 
sterilization was complete, the chamber door was briefly opened, and the syringes are 
loaded into their appropriate gun location. The PLC was then used to turn on the fan 
system, which takes 30 seconds to reach equilibrium internal pressure within the 
chamber. Finally, on the computer the appropriate program containing the geometrical 
pathway and printing parameters was run. 
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Contact Angles of Bioprinted Droplets 
 
Contact angle measurements were taken to determine the printability of different 
materials and analyze the surface interactions during deposition. Assuming compatible 
surface adhesion properties, the contact angle should be high. It is valuable to predict the 
droplet dimension at different system configurations and process conditions for planning 
the printing sequences (49). The contact angle measurements were calculated using the 
formula in Figure 2.8.  
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A 20G Micron-S tip with 0.00023cc, 0.00045cc, and 0.00135cc deposition volumes, 0 
back-off steps, 0.25mm tip height was used for all experiments. Contact angle 
measurements for 30% Pluronic F-127, 5% Protanal LF 10/60 FT, 5% Protanal LF 20/40 
were compared (n=10). 
Volume Analysis of Bioprinted Droplets 
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To determine the actual volume deposited by the bioprinter for different set dispense 
volumes, bioprinted droplets were measured in CellSens. The droplets were irregular in 
shape, so they were divided into two sections to accurately calculate the dispensed 
volume (Figure 2.9). The top half of the droplets were hemispherical in shape, and the 
volume for this portion of the drop, V&, was calculated as V& = #'𝜋r' . The bottom half of 
the drops, V#, were cylindrical in shape, and the volume was calculated as V# =(8!68")×;×<#( . The total volume for each drop was found by summing the two volumes, Total	Volume = 	V& + V#.  
 
Resolution of the Palmetto Bioprinter 
To determine the accuracy and reproducibility of the Palmetto bioprinter, droplets were 
sequentially deposited on top of a previously deposited droplet and the offsets were 
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measured. Using a 30G Micron-S Precision tip, the green droplets are deposited first with 
a dispense volume of 0.00135cc. The red droplets were deposited after gelation of the 
first droplets at a dispense volume of 0.00023cc, so the offsets from the center of the 
droplets can be quantified. Offsets were calculated as: Offsets = Green(X,Y)-Red(X,Y). 
Swelling Characteristics of Alginate Hydrogels 
Hydrogels are composed of hydrophilic polymer networks that are biodegradable and 
contain pores and void space between the polymer chains, which act to provide an 
enhanced supply of nutrients and oxygen to the cells contained within them. To 
characterize the polymer volume fraction in the swollen state, i.e. the amount of water 
that can be imbibed by the hydrogel, the swelling properties of alginate hydrogels were 
analyzed. Two experiments were performed to determine swelling properties of alginate 
hydrogels.  
The first experiment was designed to determine if the concentration of alginate, as well as 
its molecular weight, have an effect on the swelling properties of the hydrogels. This 
portion of the experiment includes the comparison of 2% and 4% LF20/40 alginate 
bioinks, as well as 4% LF20/40 and 4% LF10/60FT. LF20/40 is a high molecular-weight 
alginate, while LF10/60FT has a low molecular-weight, indicating the chain densities 
between these two polymers are different, and therefore, may have different effects on 
the materials printability and cell viability within it (54). 
To determine the effect of the concentration, and therefore availability, of the gelation 
agent, Ca#6, three different solutions were used in the substrates to form alginate 
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hydrogels: (1) 200 mM, (2) 300 mM, and (3) 400 mM CaCl2. Each gelation solution also 
included 0.9%(w/v) NaCl dissolved in deionized water. Gels were created in 12-well 
plates, with 0.5mL of calcium solution deposited on the bottom, followed by ~2.8mL of 
alginate.  
The alginate hydrogels were created by plating 0.5mL of 300mM	CaCl#	and	0.9%	NaCl 
in deionized water at the bottom of each well of a 12-well plate. Approximately 3mL of 
alginate hydrogel was then added to each well and allowed to gel overnight at room 
temperature. The next day, the gels were weighed for initial wet weights, and transferred 
to wells in a 6-well plate with 8mL of PBS (made from tablet) in each well, and placed in 
the incubator at 37℃. The gels were pulled out of the incubator on days 1, 2, 5, 6, and 7 
for weight analyses. On day 7, the swollen (wet) gels were weighed, then the gels were 
dried to determine the air-dried weight for each sample. 
The swelling properties of hydrogels include the swelling ratio, Q, the mass loss 
percentage, the equilibrium mass swelling ratio, Q!, and the water uptake content, Q). 
The swelling ratio, Q, is defined as the fractional increase in the weight of the hydrogel 
due to water absorption, and is calculated by Q = !#$!%& , where m"= is the mass of the 
hydrogel at time T, and m)& is the mass of the hydrogel at time 0. The equilibrium mass 
swelling ratio, Q!, is the mass of the hydrogel immediately post-fabrication compared to 
the mass of air-dried and calculated as Q! = !#$"' , where  W> is the air-dried weight. 
Finally, the water uptake content, Q) = !#$%"'"' × 100%.  
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Cell Distribution Within Bioprinted Droplets 
A homogeneous cell distribution within bioprinted droplets is crucial for cell 
communication, proliferation, and interconnectivity. High local cell densities are required 
for successful cell differentiation and generation of extracellular matrix. To date, 
achieving a uniform distribution of cells within bioprinted droplets has been a challenge 
in bioprinting. Current technologies typically have an aggregation of cells towards the 
innermost region of the droplet, which can inhibit cell-cell communication and 
subsequent activities, such as migration. To demonstrate the Palmetto Printer is unique in 
its ability to produce three-dimensional scaffolds with uniform cell distributions 
throughout, multiple cell types and materials were analyzed post-printing.  
A 0.62% Collagen and 4% LF 20/40 (1:1) blend bioink was seeded with Human Adipose 
Microvascular Endothelial Cells (HAMEC) and Normal Human Dermal Fibroblasts 
(NHDF) at a 1:4 ratio with a cell density of 1,000,000 cells/mL (n=5). A 5% LF 20/40, 
high molecular-weight alginate, was seeded with NHDF only at 1,000,000 cells/mL 
(n=9). Additionally, 5% LF 10/60 FT, low molecular-weight alginate, was seeded with 
HAMECs at 1,000,000 cells/mL (n=7).  
The bioink was then loaded into printer syringes, transported to the printer, and printed in 
a 5 x 2 dot array onto a gelatin/TiO# substrate.  The following printing parameters were 
used: deposition volume of 0.00045 ml, deposition rate of 0.010	!+? , tip height of 0.1 
mm, 10 backsteps, stage temperature of 4℃, a height of 15 mm the syringe was lifted 
between depositions, and a 22-gauge plastic tip (Fishman). The constructs were allowed 
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to gel for 40 minutes.  While the constructs were gelling, a fluorescent-based stain 
(Invitrogen Life Technologies) was made following the protocol of the kit.  The cell-
laden hydrogels were then immersed in the stain for 15 minutes, in the dark, prior to 
imaging. All of the fluorescent images were taken on a Leica TCS SP2 AOBS confocal 
microscope system using Z-stack parameters of 103 optical slices over a 326.40µm 
depth. Pictures of each droplet were taken individually. These images were then imported 
into CellSens software and each was sectioned into quadrants and concentric circles. 
Cells were manually counted for the entire droplets and each section within the droplets.  
Cell Viability in Bioprinted Constructs 
To quantify the viability of the constructs, stain them using a fluorescent-based 
viability/cytotoxicity assay, and image using confocal microscopy. Following the kit 
instructions, prepare a staining solution containing calcein AM and ethidium homodimer-
1. To make 10 mL of staining solution, add 20 microliters of the ethidium homodimer-1 
and 5 microliters of the calcein am to 10 mL of sterile, tissue culture-grade Dulbecco’s 
Phosphate-Buffered Saline (+magnesium, +calcium; DPBS++). Image the stained 
constructs using a confocal microscope system at days 0 and 8. Take multiple pictures of 
each bioprinted construct, using Z-stack parameters of 30 optical slices over a 300𝜇m 
depth, and manually count the cells. If cells appear yellow or green they are counted as 
alive, and if red, they are counted as dead.  
Cell viability was calculated using the following formula:  
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Viability = 	 #	4B*C	DC44?	(1ECCF6GC443))#	H3HI4	DC44?	(1ECCF6GC443)6EC>) × 100%. 
Cell Proliferation in Bioprinted Constructs 
To quantify the amount of cell proliferation within the bioprinted constructs, they were 
stained with a fluorescent-based viability/cytotoxicity assay on day 0 and 8, and imaged 
using confocal microscopy. Multiple pictures were taken of each bioprinted construct 
with Z-stack parameters of 30 optical slices over a 300𝜇m depth, and the cells were 
manually counted.  The amount of cell proliferation in bioprinted constructs over 8 days 
was calculated using the following equation: 
Proliferation = 	 #	4B*C	DC44	D3JFH	3F	>IG	K#	4B*C	DC44	D3JFH	3F	>IG	- × 100%.   
2.7 RESULTS 
RGD Peptide Conjugation Analysis 
To analyze the success of RGD peptide conjugation on the alginate bioink, a comparison 
experiment was performed using cell-laden, RGD-conjugated 15% concentration, 5% 
oxidation alginate bioink and cell-laden, non-conjugated 15% concentration, 5% 
oxidation alginate bioink. DAPI staining for nuclei and phalloidin staining for actin were 
used to analyze the cell spreading in printed constructs on day 8. Images of each sample 
(at least three random pictures per sample) were taking using a confocal microscope 
system using Z-stack parameters of 30 optical slices over a 300𝜇m depth (Figure 2.14 
A,B).  
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The cell spreading shown in the sample with RGD-conjugated alginate proves the 
successful incorporation of the peptide on the alginate. Additionally, Jia, et. al., who we 
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worked in collaboration with for this project, previously demonstrated that the cell 
adhesive and migratory properties were not limited to certain regions of the construct, but 
occurred throughout (Figure 2.14C, 37). Cell migration is an important step in tissue 
development, therefore the conjugation of RGD peptides on alginate improves the 
likelihood of in vivo application using this bioink. 
Contact Angles of Bioprinted Droplets 
A 20G Micron-S tip with 0.00023cc, 0.00045cc, and 0.00135cc deposition volumes, 0 
back-off steps, 0.25mm tip height was used for all experiments. Contact angle 
measurements for 30% Pluronic F-127, 5% Protanal LF 10/60 FT, 5% Protanal LF 20/40 
were compared (n=10; Figure 2.15).  
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For the smaller dispense volumes, 230 nL and 450 nL, there were significant differences 
between the materials tested. However, all of the materials tested had appropriate contact 
angles (> 90°), indicative of maintained tension in the vertical direction, a requirement 
for the printability of these materials. Therefore, all three of these biomaterials could 
serve as vehicles for the construction of cell-laden constructs based on this requirement. 
Volume Analysis of Bioprinted Droplets 
Dispense volumes for acellular 5% LF20/40 alginate were measured using CellSens 
(n=10). A dispense volume of 0.00135cc with a 0.30mm tip height and 0 back-off steps 
was used to compare the volumes dispensed when using a 27G versus 30G Micron-S 
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Precision Tip. The two tips were shown to deposit significantly different volumes 
(P<0.006), which highlights the decreasing volume with increase of tip gauge size, i.e. 
decreased diameter with increasing gauge size of the tip (Figure 2.16). This suggests that 
the volume of deposited droplets is dependent on gauge size, and that due to the increased 
surface tension in the smaller diameter tips they dispense a smaller volume than the larger 
diameter tips.   
 
Resolution of the Palmetto Bioprinter 
The resolution of the Palmetto Printer was found to be 10 nanometers (Figure 2.17). The 
results demonstrate the bioprinter is capable of depositing cell-laden hydrogels in specific 
three-dimensional locations accurately and consistently using computer-aided software. 
The software determines the placement of each droplet and controls many of the 
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parameters for dispensing (Figure 2.5). The repeatability of the bioprinter to 
appropriately deposit biomaterials is fundamental to its success in tissue engineering 
applications. 
 
Swelling Characteristics of Alginate Hydrogels 
The day 1 swelling ratio, Q, was analyzed because that was the time point at which the 
most mass increase was observed in all hydrogels compared to any other time in culture 
over 7 days.  
Independent t tests were used to compare 2% LF20/40 and 4% LF20/40 over 7 days 
(n=8), and determine the impact of alginate concentration, i.e. polymer density, on the 
swelling properties of the hydrogels (Figure 2.18). The day 7 swelling ratio, Q, between 
the two group was not different (P<0.461). Additionally, the water uptake content, Q), 
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for the two hydrogels was not different (P<0.336). There were no significant differences 
between these two groups, which suggests that the concentration of the alginate has 
minimal effect on the materials’ water absorption properties. 
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LF 20/40 is a high molecular weight alginate, and LF 10/60FT is a low molecular weight. 
To determine the effect of polymer network density, the two materials were compared 
(Figure 2.19). 
 
The second half of this experiment aimed to discern whether the availability of the 
gelation agent, in this case Ca#6, in the substrate has an effect on the swelling properties 
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of alginate hydrogels. 4% LF10/60FT gels made with three different concentrations of 
calcium in the substrate were compared in Figure 2.20. Interestingly, there were no 
significant differences between any of the groups for the varying concentrations of Ca#6.  
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2% LF20/40 alginate hydrogels created in varying concentrations of calcium were 
compared in Figure 2.21. The day 1 swelling ratios, Q, were significantly different for all Ca#6concentrations when analyzed with independent t-tests. However, there was no 
difference between the day 7 swelling ratios. This indicates that at earlier time points the 
hydrogels are more susceptible to ion exchange with their surrounding media, and 
eventually reach an equilibrium by day 7.  
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The significant differences seen in the higher molecular weight alginate, but not in the 
lower molecular weight, imply that the density of the polymer network does have an 
effect on the water-absorption capacity of the hydrogel. These studies suggest that as the 
density of the polymer network increases, so do the water absorptive properties of the 
material. This was further validated by the comparisons of the high- and low-molecular 
weight alginates in Figure 2.19.  
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Cell Distribution Within Bioprinted Droplets 
Cell homogeneity was determined by sectioning the bioprinted droplets into quadrants, as 
well as concentric circles to evaluate the distribution of cells within different biomaterials 
after the bioprinting process. The cell distributions were then analyzed in SPSS Statistics 
software using ANOVA to determine if there was any difference with respect to cell 
density in the different areas.  
For the NHDFs suspended in 5% LF20/40 alginate (Figure 2.22) bioprinted droplets 
sectioned into quadrants (n=10) the calculated F value was 1.572 (P<0.215), which was 
less than the critical value of F (2.901). Therefore, there was no difference between cell 
distribution in the different quadrants indicating a homogeneous cell distribution 
throughout the bioprinted droplet.  
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For the droplets sectioned into concentric circles (n=10) the calculated F value was 6.463, 
P<0.005, which indicates there is a difference in cell distribution between the different 
concentric regions. To determine which regions were different from one another, 
independent t tests were performed in SPSS statistics to compare all of the groups. When 
the outer and middle rings were compared, the calculated P value was P<0.234, which 
suggests there was no difference in number of cells between these two groups. When the 
outer and inner concentric rings were compared, the calculated P value was P<0.332 
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indicating no difference between these groups. Finally, when the middle and inner 
concentric rings were compared, the P value was found to be P<0.027. Therefore, there is 
a significant trend of a denser cell population within the middle concentric ring as 
compared to the inner-most portion of the bioprinted droplet for this bioink. 
For the 0.62% collagen and 4% LF20/40 alginate blend (1:1; n=5; Figure 2.23) sectioned 
into quadrants the calculated F value was 2.101 (P<0.140), which was less than the 
critical value of F for P<0.05. For the droplets sectioned into concentric circles the 
calculated F value was 1.083 (P<0.369), which was also less than the critical value of F 
for P<0.05. Therefore, there was no difference in the distribution of cells between the 
different quadrants or concentric circles of the bioprinted droplets using the 
collagen/alginate blend bioink.  
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The F value calculated for NHDFs suspended in 5% LF10/60FT alginate (n=9; Figure 
2.24) bioprinted droplets sectioned into quadrants was 1.963 (P<0.139), which was less 
than the critical value of F for P<0.05, indicating there was no difference in cell 
distribution between the different quadrants of the bioprinted droplets. For the NHDFs 
suspended in 5% LF10/60FT alginate sectioned into concentric circles, the calculated F 
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value was 23.084, which was greater than the critical value of F, 19.45, for P<0.05. 
Therefore, there was a difference in cell distribution between the different regions of the 
bioprinted droplet. To determine which regions were significantly different from one 
another, independent t tests were run in SPSS statistics.  
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When the inner and outer rings were compared, the significance was P<0.001925 with a 
definite trend of more cells being located in the inner concentric circle as compared to the 
outer. When the outer and middle rings were compared, the significance was P<0.000267 
with more cells being located in the middle ring than the outer. Finally, when the middle 
and inner rings were compared the significance was P<0.180344 indicating there was no 
difference in the cell distribution between these two regions. Therefore, for the 5% 
LF10/60FT bioink there is a trend of cell distribution towards the interior of the 
bioprinted droplets.   
Cell Viability in Bioprinted Constructs 
Cell viability, one of the requirements of a successful bioprinting technique, was 
analyzed 1 hr and 8 days post-printing. High cell viability is essential for fabricating 
biomimetic constructs and is a direct representation of an adequate bioink. RGD peptide 
conjugation improves cell viability over extended periods of time by promoting cell 
spreading. Fluorescent microscopy was used to quantify cell viability in constructs after 
the printing process. Alginate bioink with a concentration of 15% and oxidation of 5% 
had average day 0 viability of 98%, day 4 of 96%, and day 8 of 95% (Figure 2.25). An 
independent t test was performed to determine the significance of the difference between 
cell viabilities on days 0 and 8, and a P-value of P<0.002 suggests the viability 
significantly increased over the culture time period.  
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These results indicate the deposition technique of the direct-write bioprinter extrudes 
cells gently enough to produce constructs that remain viable during and after the printing 
process. The high cell viability shows the 5% oxidation and 15% concentration alginate 
bioink was a suitable vehicle for cell deposition and provided an adequate environment 
for cell-survival. Similar cell counts in each of the areas showed a homogeneous cell 
distribution in the alginate bioink, a fundamental aspect of printing resolution.  
Cell Proliferation in Bioprinted Constructs 
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Most tissues have complex combinations and gradients of extracellular matrix 
constituents, each with specific biological and mechanical influences. A biomaterial 
should be biomimetic of the native environment and facilitate cellular functions. The high 
porosity of the alginate scaffold allows the cells to communicate and network with each 
other, and may also facilitate the flux of nutrients and metabolites between the scaffold 
and its surrounding environment. Cell adhesion to the extracellular matrix is a 
preliminary phase of tissue formation that happens before cell proliferation and the 
organization of extracellular matrix molecules into functional tissue. The proliferation of 
cells plays a vital role in wound healing and tissue growth, and is therefore a very 
important factor when analyzing bioprinted constructs for tissue engineering applications. 
The RGD-conjugated alginate enhanced cell attachment in printed constructs, leading to 
improved cell spreading and proliferation. The proliferation of cells in the printed 
scaffolds was quantified by counting three separate areas on days 0 and 8 (Figure 2.26).  
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The overall cell proliferation was found to be 219.674% after 8 days of culture. These 
results signify the scaffold has adequate biocompatibility to be used as a synthetic 
extracellular matrix for delivering cells to repair damaged or nonfunctional tissue.  
2.8 DISCUSSION 
Presented here is a 3D robotic bioprinter that reliably and consistently dispenses 
homogenous drops of individual cells or cells mixed with biomimetic hydrogels (37). 
There are critical aspects of the design process that impact the generated construct’s 
biomimetic function (35,36). The ability to control the temperature of the biomaterial and 
substrate is essential for the gelling mechanism of the hydrogels and the maintenance of 
their mechanical properties, therefore influencing cell distribution, proliferation, and 
differentiation within the hydrogel. Organs consist of many cell types, so the multiple 
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dispensers are critical for producing heterogeneous, tissue-like structures. The computer-
aided design of the external architecture allows the production of custom tissue 
substitutes for distinct wounds or tissues. This is essential for the development of patient-
specific replacements. The internal architecture is equally important because it affects the 
cell-cell relationships within the structure by placing the proper cells in intimate contact 
with each other and allowing them to form in vivo-like cell-cell junctions. Precise 
placement of cells determines how the cells communicate and network with each other to 
form vascular networks and mimic their bioactivity in native tissues. Three-dimensional 
bioprinting provides homogeneously dispersed cells within the bioink, as well as 
excellent precision on spatial placement of the cells themselves (33). Generated scaffolds 
also have high local cell densities, which is essential for cell differentiation and the 
formulation of extracellular matrix. 
The bioprinter implemented here comprises a unique temperature-controlled 
environment in which the cells and cell-hydrogel mixtures are not limited by the 
necessity of pre-fusion. Under these conditions, the bioprinter is not solely reliant on the 
differential adhesion hypothesis. The inclusion of hydrogel materials can help guide the 
cell distribution and allow the cells to fuse, or not, depending on the properties desired 
for specific experimentation. The selection of biomimetic hydrogels for cell-
encapsulation also has a profound effect on cell phenotype. Materials are known to have 
an effect on cell attachment, as well as cell size and morphology (36). The rheological 
characteristics, such as viscosity, of hydrogels dictate their influence on the cellular 
microenvironment (35). Native alginate is inert and does not readily communicate with 
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cells participating in the control of phenotype. However, using alginates that are 
chemically modified via peptide conjugation and oxidation, produces constructs with 
controlled degradability and increased cell attachment, migration, and proliferation (39). 
Altering the physiochemical properties of a biomaterial can influence tissue development 
in vivo (35,41). 
Three-dimensional bioprinting using a fluid-dispensing, direct-write machine is 
limited by the degree of resolution of printed constructs, the availability of hydrogel 
materials, initial cell death post-printing, and the ability to vascularize the biomimetic 
scaffolds (32,41,42). An important feature of the bioprinting is its resolution. Every 
printing method is defined by the lower technical limit size of the smallest achievable 
details. There is a dynamic relationship between the lower limit size and attainable scale 
of the printed construct: the higher the resolution of the minute details, the smaller 
maximum construct size (9). The bioprinter is capable of depositing volumes as small as 
230 nL in highly specific and organized patterns, giving it a higher resolution than similar 
machines. Hydrogels have been commonly used in bioprinting due to their 
hydrophilicity, biocompatibility, structural similarity to the extracellular matrix, and ease 
of modification (10-16). The high-water content of hydrogels improves their 
biocompatibility, but greatly reduces their mechanical strength and printability (33). 
There is a lack of optimal hydrogels with the appropriate mechanical properties for fluid 
delivery during bioadditive-manufacturing extrusion. Therefore, there is a large demand 
for developing hydrogels that are immunologically inert, have cytocompatible gelation 
mechanisms that can be successfully extruded using fluid delivery, and also produce a 
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cell-laden matrix with an optimal range of mechanical properties (2). Before the printing 
process, the cell-laden hydrogel bioink must be stored in the syringes for an amount of 
time, compromising the cell’s viability (33). During the printing process, the shear stress 
induced on cells during extrusion can also be harmful to their viability (2,43). The 
bioprinter is able to produce highly viable (>90%) constructs, therefore overcoming the 
issue of initial cell death.  
Vascularization plays a vital role in transmitting, supporting, or preserving the 
biomimetic function of bioprinted constructs (43). The diffusion of oxygen is 100 −200𝜇m; therefore, in larger bioprinted constructs hypoxia is a concern (9). Conventional 
techniques are incapable of producing constructs with embedded vasculature, greatly 
limiting the size of producible scaffolds. The cell viability assessment of the bioprinter 
showed significant cell proliferation in the printed constructs over 8 days. Therefore, the 
technique proves its ability to generate scaffolds that allow cell growth, communication, 
and the formation of networks, requirements of vascularization.  
The bioprinter provides the ability of using a variety of materials to quickly 
deposit cell-laden hydrogels in specific patterns. While this technique produces 
heterogeneous constructs with tunable properties, it is incapable of concurrent deposition, 
i.e. multiple syringes depositing at once, and reactive mixing, such as core-shell 
bioprinting discussed in chapter one. For some biomaterials, this deposition method 
would enhance the gelation mechanism and shorten the time for scaffold production (35). 
The addition of a multi-syringe dispenser could allow a broader range of biomaterials for 
the biofabrication technique. Investigation of cell activity in bioprinted constructs over a 
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longer period of time would provide more information about hydrogel characteristics, cell 
network formation, and vascularization of the constructs. These methods provide the 
possibility of producing vascularized replacements for future applications because the 
constructs are produced with high local cell densities and allow cell-cell interactions, 
which improves the likelihood of post-implantation survival (12,29). 
The bioprinter’s deposition method described can further involve robotically 
positioning and driving the three dispensers to deposit a plurality of biological materials 
on top of previously deposited materials in a predetermined pattern. This step can be 
repeated using ascending patterns until a three-dimensional organ or tissue is produced. 
Therefore, the Palmetto Printer is suitable for reliably dispensing cell-laden hydrogels to 
create a three-dimensional construct that is capable of retaining vasculature and high cell 
viability, and could be used in a variety of future tissue engineering applications.  
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CHAPTER THREE 
SCAFFOLD-FREE TISSUE ENGINEERING 
The field of tissue engineering advances an exciting array of solutions for organ 
repair and wound healing. However, to realize this potential, several hurdles must be 
overcome. Vascularization is arguably the most important practical limitation in tissue 
engineering, imposing both dimensional and time constraints on the technology. 
Vascularization and fast anastomosis with the host are essential in engineering cellular 
constructs that survive once implanted, as well as tissue maintenance and regeneration. 
Endothelial cell migration and physiological growth of new blood vessels in vivo has 
been reported to occur at ~5 um/hour due to the availability of oxygen, which is limited 
to a diffusion distance of 150 − 200𝜇m from a supplying blood vessel (Figure 3.1) (42-
43). This diffusion limit is relative to the distance between mammalian cells and an 
adjacent vascular bed (Lovett). With the clinical need being for larger engineered tissues, 
a major focus in the tissue engineering field has been on designing constructs with pre-
existing vascular architectures or, more recently, prevascularized constructs.  
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Vascularization of an avascular tissue, or a tissue graft, can be modeled by a well-
ordered series of events (Figure 3.2), starting with (1) endothelial cell activation, (2) 
migration of endothelial cells and remodeling of the implant stroma, (3) Primitive 
network formation (4) anastomosis of host/implant endothelial structures, (5) Network 
remodeling (6) Lumen formation within the endothelial architecture, and (7) maturation 
of vessels through recruitment of mural cells. This leads to formation of a blood-perfused 
vascular pedicle in an implant. Depicted is the expected entry point of different implant 
types, with preceding development either occurring in vitro or supplied by donor.   
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Current engineered grafts, such as the bioprinted constructs discussed in chapter 2, are 
absent of any vascular architecture, forcing them to enter the vascularization pipeline at 
the earliest time point. Rather than incorporating intricate microvessel architectures into 
our bioprinted constructs, we began investigating scaffold-free fabrication methods. 
Scaffold-free tissue engineering aims to produce physiologically-relevant three-
dimensional multicellular constructs without the use of a scaffold.  
 
3.1 SCAFFOLD-FREE CELLULAR SELF-ASSEMBLY 
 
Scaffold-free engineering techniques rely on the inherent capacity of cells to 
migrate and form intercellular connections. Adherent cells, like endothelial cells and 
fibroblasts, depend on the formation of these intercellular as well as extracellular matrix-
cellular connections for survival. When adherent cells are placed in an environment that 
lacks a surface for adhesion or a substrate, the cells will aggregate and undergo the 
process of self-assembly. During the process of self-assembly, suspended cells form 
three-dimensional multicellular spheroids. This process mimics processes known to occur 
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during embryogenesis, morphogenesis, and organogenesis in vivo (Achilli, 2012). The 
produced multicellular spheroids have similar architectural and functional characteristics 
of native tissues.   
 
3.2 PREVASCULARIZATION: PRIMARY NETWORK FORMATION 
To sustain larger tissue engineered constructs, an intact vascular pedicle 
consisting of an inlet, outlet, and a perfusable capillary bed, must either pre-exist or form 
rapidly upon implantation. Prevascularization has recently been explored in tissue 
engineering in attempts to accelerate the acceptance of implanted cellular constructs. 
These techniques aim to produce implants with a preformed microvasculature prior to 
implantation. Prevascularization refers to the in vitro assembly of primitive endothelial 
networks resembling a capillary bed.  
 79 
In recent years two strategies for vascularization of tissue engineered constructs 
have been explored: angiogenesis and inosculation. The angiogenesis approach relies on 
the ingrowth of vascular sprouts from the host microvasculature (indicated by the red 
vessels in Figure 3.4A) into the implanted construct, which overtime fuse together to 
form a new microvascular network (12). This process is highly dynamic and must 
progress through the entire vascularization pipeline depicted in Figure 3.1. The 
inosculation approach incorporates a preformed microvascular network prior to 
implantation (depicted by the blue vessels in Figure 3.4B) that forms interconnections, or 
inosculates, with the host vasculature to get a fully blood-perfused vessel within a short 
amount of time (12).  
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Laschke and Menger make a useful distinction between angiogenesis and 
inosculation that explains the utility of prevascularization: angiogenic sprouting, while 
potentially faster than de novo vasculogenesis, is still a slow process, whereas 
inosculation, or the merging of existing microvessels into larger diameter vessels, occurs 
more rapidly (12,14,43-44). Specifically, in vivo microvessel growth occurs at a peak rate 
of 5 µm hrC  (12). Therefore, spanning an entire implant exceeding dimensions of a few 
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hundred micrometers at this rate is too slow to prevent ischemic damage, as hypoxia 
peaks in skeletal muscle at approximately eight hours (9,12). 
3.3 DEVELOPMENT OF NOVEL SCAFFOLD-FREE PREVASCULARIZED 
ENDOTHELIAL-FIBROBLAST CONSTRUCTS  
Engineering these vascularized implants in vitro requires the use of multiple cell 
sources to form the multiple components of vessels including the lining of the vessels, 
which is predominantly made up of endothelial cells, and the supporting cellular network 
(41). We have developed and previously reported on the anastomotic potential of a 
scaffold-free prevascular implant model that is formed from the coculture of human 
adipose microvascular endothelial cells (HAMECs) and normal human dermal fibroblasts 
(NHDFs) (5,23,25-26). We use primary human adipose derived endothelial cells to 
ensure clinical translatability, where an autologously derived population of cells can be 
re-implanted in a patient with minimal morbidity due to immune compatibility 
complications. The adult fibroblasts create the extracellular-rich stroma necessary to 
support a vascular bed and provide additional proangiogenic stimuli (22). Mature 
endothelial cells, while capable of forming spontaneous capillary like tubes in vitro, 
appear to require consistent input of proangiogenic environmental signaling. Fibroblasts, 
through constitutive expression of vascular endothelial factor (VEGF), basic fibroblast 
growth factor (bFGF) and angiopoitin-1 (Ang-1), address this basic need (22). The 
presence of fibroblasts corresponds to an increased microvessel density within an implant 
and stabilization of vessels by signaling endothelial cell to express smooth muscle actin 
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(16). Other exctacellular matrix proteins deposited by the fibroblasts such as laminin, 
collagen type I and collagen type IV are needed for vessel maturation (10).  
We have previously reported that a specific 1:4 ratio of human microvascular 
endothelial cells and fibroblasts maximizes the density of endothelial cords when allowed 
to self-assemble in a scaffold-free non-adherent environment. Increasing the density of 
fibroblasts resulted in endothelial clusters without cords, and increasing density of 
endothelial cells resulted in structures lacking avascular stromal areas consistent with a 
vascular bed (23). Additionally, these endothelial cords were shown to organize into 
vascular networks with distinct directional orientations that reflect self-assembly-
mediated tension (25; Figure 3.5).  
 
Within 3 days of in vitro culture in an agarose mold, the coculture generated an 
extracellular matrix containing laminin, type I collagen, and fibronectin. The interplay 
between ECM components, such as laminins and fibrillar collagen, and cell surface 
integrins play a key role in vascular lumen formation (24).  
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Due to the diffusional limits of oxygen and nutrients to the interior of implanted 
constructs, we wanted to take a more systematic approach to investigate the 
vascularization process and how engineered constructs get perfused once implanted. The 
literature reports findings from later time points post-implantation, spanning from a few 
days to even more than a week post-implantation, to assess graft acceptance. However, 
this data is incomplete as it does not evaluate the dynamics of vascularization at early 
time points following implantation. Additionally, ischemic damage to tissues occurs 
within a time span of hours rather than days, necessitating a focus on processes impacting 
vascularization within a 24-hour post-implantation window.  Therefore, we wanted to 
investigate the early temporal kinetics of vascularization, i.e. <24 hours post-
implantation, of implanted cellular constructs, in order to discern the immediate events 
happening post-implantation. Specifically, we hypothesized that the existing self-
assembled primitive network of the Scaffold-free Prevascularized Endothelial-fibroblast 
Constructs (SPECs) will allow earlier host-implant anastomosis and increased presence 
of lumen containing vessels in the interior of the implants by 24 hours compared to 
avascular grafts, such as fibroblast spheroids.  
 
3.4 MATERIALS AND METHODS 
 
Formation of Non-adherent Agarose Molds 
A 2% (w/v) agarose solution is made by dissolving the agarose in deionized water. To 
sterilize the solution, it is autoclaved on the liquid cycle for thirty minutes. The geometry 
of the agarose mold is determined by the computer-aided design used to create the 
 84 
negative in which the agarose is gelled around. This provides the opportunity for using 
patient-specific images to create physiologically-relevant SPECs in the future. 
 
 
Cell Culture 
Human adipose microvascular endothelial cells (HAMEC) (ScienceCell, Carlsbad, CA, 
7200) were cultured in T75 cell culture flasks with endothelial growth medium-2 (EGM-
2) (Lonza, Allendale, NJ, CC-3156 & CC-4176) until reaching 80% confluence. Normal 
human dermal fibroblasts (NHDF-Ad) (Lonza, CC-2511) were cultured in Fibroblast 
growth media-2 (FGM-2) (Lonza, CC-3131 & CC-4126). Cells were collected between 
passages for use in experiments.  
 
Formation of Scaffold-free Prevascularized Endothelial-fibroblast Constructs  
We have developed and previously reported on the anastomotic potential of a scaffold-
free prevascular construct that is formed from the coculture of human adipose 
microvascular endothelial cells (HAMECs) and normal human dermal fibroblasts 
(NHDFs) (5). In previous work, Czajka, et. al. determined the appropriate ratio of 
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fibroblast to endothelial cells to be 4:1 (5,23,25-26). The scaffold-free prevascularized 
endothelial-fibroblast constructs (SPECs) were modifications of the protocol established 
by Czajka and Drake (23). Rod-shaped troughs of 0.9 cm length by 0.1 cm width by 0.5 
cm depth were constructed in 2% UltraPure Agarose (Invitrogen, Carlsband, CA, 16500-
100) and high density 4:1 mixtures of 720,000 NHDF-Ad cells and 180,000 HAMECs 
were pipetted into the troughs of the agarose mold. Cells were then cultured in a 2:1 
mixture of FGM-2 and EGM-2 for 3 days. Implants were either collected in Dulbecco’s 
Phosphate Buffered Saline for use in surgical implantation or collected and fixed in 4% 
paraformaldehyde for histology. Fibroblast-only spheroids (FOS) were constructed 
similarly with 900,000 NHDF-Ad and no HAMECs. Silicone fragments of rectangular 
box dimensions of 0.6 cm by 0.1 cm by 0.1 cm (to match the eventual dimensions of the 
cell-based rods) were autoclaved and stored in DPBS in preparation for implantation.  
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Immunohistochemistry Analysis of SPEC 
Tissue sections were fixed in 4% paraformaldehyde solution for thirty minutes 
and subjected to hematoxylin and eosin staining, direct or indirect immunofluorescence 
labeling. Tissue sections were directly labeled with Hoescht 33342 nuclear stain 
(Molecular Probes, 1:10,000), and Alexa FluorTM phalloidin 488 (ThermoFisher 
Scientific A12379, 1:500) for F-actin. Selected sections were stained with primary 
antibodies to von Willebrand Factor (Abcam, Catalog# ab6994, 1:1000), CD31 (Abcam 
ab28364, 1:50), human CD31 (monoclonal antibody) (R&D Systems BBA7, 1:25), 
smooth muscle actin (ThermoFisher Scientific PA5-19465, 1:1000). Primary antibodies 
were fluorescently tagged with the secondary antibodies Alexa FluorTM goat anti-mouse 
488, goat anti-rabbit 546, goat anti-mouse 546, and goat anti-rabbit 633 (ThermoFisher 
Scientific, A-11001,11035,11030,21070, 1:500). Sections were mounted on Colormark 
Plus microscope slides in Prolong Gold antifade reagent (Molecular probes P36934).  
Western Blot Analysis 
SPECs and FOS were collected after 1, 2, and 3 days of culture in 2% linear agarose 
molds as previously described. Samples were snap frozen, and mechanically 
homogenized in RIPA lysis buffer with protease inhibitor cocktail. Samples were 
maintained in constant agitation for 2h at 4°C, centrifugated for 20 min at 16,000 g at 
4°C. Supernatant was stored in fresh tube at -20°C. PierceTM BCA Protein Assay kit 
(Thermofisher Scientific 23227) was used to estimate protein concentration for samples 
as per manufacturer’s instructions. Prior to gel electrophoresis, samples were diluted in 
RIPA buffer to attain 20 ug of protein in 20 uL solution, and further diluted 1:1 in 2x 
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Laemmli Sample buffer to attain 40 uL loading volumes. Samples were loaded onto Any 
kDTM Mini-Protean® TGXTM Precast Protein Gels. Following protein separation and 
overnight transfer onto PVDF membranes, western blots were performed using 
antibodies towards GAPDH (loading control) (CalBioChem CB1001, 1:1000), VEGFR2 
(Abcam ab39256, 1:900), VE-Cadherin (ThermoFisher Scientific 36-1900, 1:250), vWF 
(Abcam, ab6994, 1:500), and DLL4 (Abcam ab7280, 1:1000). 
Endothelial Cell Migration out of the SPEC in vitro 
To investigate whether the SPEC could promote vascularization, we looked at the 
behavior of the embedded endothelial cells when placed in an acellular environment. 
Endothelial cells were tagged with GFP following the protocol. In this study, the SPEC 
was placed in the center of a well of a cell culture dish and monitored using the 
LionHeartFX Live cell imager (Biotek) over 7 days (Figure 3.8). 
 
Microscopy and Quantitative Analysis of Endothelial Cord Organization 
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Confocal images were acquired using Leica TCS SP5 AOBS Confocal Microscope 
system (Leica Microsystems Inc., Buffalo Grove, IL) and collected as average projected 
z-stacks at 20x and 40x magnifications. Stitching was performed using LAS AF v2.6.3 
Build 8173 and encompassed the entire visible cross section of each implant. Images 
were auto-enhanced and analyzed using ImageJ (NIH, Bethesda, MD). To analyze 
endothelial cord organization, stitched 40x (512x512) confocal images of sections stained 
with antibodies for vWF and CD31 were segmented as follows. Average projected 
images (10um depth) were auto-thresholded in ImageJ (Otsu auto threshold; 29), and 
binarized. Perimeter of the implants and endothelial capsule around implants were drawn 
freehand. Binary images were used to calculate microvessel area fractions of the implant.  
Binary images were skeletonized using an ImageJ plugin, provided by Arganda-Carreras 
et al, with branches pruned by lowest intensity voxel (30). Resulting images was used to 
calculate number of junctions and vessel branch lengths.  
Animal Model Development 
Animal procedures were conducted following the approval by Institutional Care and 
Animal Use Committee (IACUC) of the Medical University of South Carolina. Fifty-four 
Sprague Dawley rats (Charles River Labs, Wilmington, MA) were divided into three 
groups: SPECs (n=15), FOS (n=15), and silicone implants (n=15). Nine rats were set 
aside for sham surgeries. Surgeries were performed as described by Calder, et al. 
Implants were placed in submuscular pocket, with the long axis oriented parallel to the 
hind limb running proximal to distal. Five rats within each implant group were sacrificed 
at 6hr, 12hr, and 24 hours with muscle excised from the left hind limb en bloc with 
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implant or sham surgery, placed in O.C.T. Compound (Tissue-Tek 4853, Torrance, CA) 
and frozen at −80℃ for cryosectioning. Muscle from the right hind limb was harvested 
for comparison.  
 
Statistical Analysis 
Statistical Analysis was performed using IBM SPSS for Windows Version 24.0 
(Released 2017, Chicago, SPSS Inc). Levene’s test for homogeneity of variance was used 
to determine equality of variances (α=0.05). For data with equal variance between 
groups, One-way ANOVA was performed with post hoc application of Bonferroni’s t test 
used to compare microvessel density, degree of penetrance of vessels, and branching 
density among the three implant types at each time point. For data with unequal 
variances, Welch’s one-way ANOVA was performed with Dunnett T3 post-hoc 
corrections.  
Scalability of the SPEC Technology 
The most important part of developing cellular technologies for tissue engineering, is the 
feasibility of scaling these constructs to physiologically-relevant sized tissues. To assess 
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the possibility of scaling this technology to larger, more complex geometries, we created 
a honeycomb structure consisting of the cells equivalent to nine SPECs, including 6.48 
million NHDFs and 1.6 million HAMECs.  
3.5 RESULTS 
In vitro Analysis of Scaffold-free Prevascularized Endothelial-fibroblast Constructs 
When we analyzed the SPECs in vitro, we observed a high abundance of primary 
vascular networks, indicated by CD31. The minimum requirements for primary network 
formation are endothelial cells and synthetic cells, like fibroblasts, that together secrete 
extracellular matrix. As indicated here by CD31 there are dense endothelial networks 
within these scaffold-free constructs, surrounded by extracellular matrix, indicated by 
Phalloidin staining for F-actin (Figure 3.10). 
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Rate of Endothelial Cell Migration out of the SPEC in vitro 
A time-series image of GFP-tagged HAMECs within the SPECs placed on a tissue 
culture plate demonstrated a high degree of motility of the endothelial cells following 
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three days of culture, with some cells tracked as traveling over 400 µm in distance within 
a 24h time series (Figure 3.11).  
 
Western Blot Analysis 
Prior to implantation, the SPECs presented with vWF, VEGFR2 and VE-cadherin as 
indicated by (FIGURE 3.12). Control FOS implants displayed negligible levels of these 
vascular markers. Western blotting for DLL4, a marker of endothelial tip cell phenotype 
showed increased levels at days 1 and 2 of SPEC incubation but decrease by day 3 
compared to FOS controls. 
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Quantitative Analysis of Endothelial Cord Organization 
Implant vascular structures (CD31 or vWF+) were segmented based on 
immunofluorescent images of tissue cross sections (10 µm depth) containing the entire 
implant cross section as well as an intact muscle/implant interface (Figure 3.13A). 
Endothelial structures in direct connection with this interface and the endothelial capsule 
surrounding the implant were segmented separately (green) from the vascular structures 
found within the interior of the implants (yellow). Total microvessel area fraction, or the 
percentage of the implant cross sectional area containing vascular elements, was 
calculated for each implant, with comparisons made between implant types at the 6h, 
12h, an 24h time points (Figure 3.13B). Microvessel area fraction excluding the 
endothelial capsule at the muscle/implant interface was calculated for each implant 
(Figure 3.13C). The fraction of endothelial cords that penetrate the implant interior was 
calculated by dividing the length of the cords found excluding the capsule vessels by the 
total length of the vascular network (Figure 3.13D). This fraction is a surrogate marker 
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of the invasiveness of the vessels within and surrounding each implant within the host. 
Junction density was calculated as the number of vessel branch points found per um2 of 
the implant cross sectional area (Figure 3.13E-F). Similarly branching density was 
calculated as the number of branches per um2. These two metrics assess the branching 
complexity of the developing vascular networks in each implant type across time. 
Microvessel area, junction density, and branch density of SPECs remain significantly 
elevated compared to other implants at all time points. Fibroblast spheroids demonstrated 
the most growth in terms of microvessel area and penetrating tubule fraction between 12 
and 24h with branch density resembling the SPECs at 24h.  
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Assessment of Short-term SPEC Implants (<24 hours) 
All three implant types developed a CD31 and vWF-positive capsule as early as 6h post-
implantation, indicating early endothelialization of the host-implant interface (Figure 
3.14). The SPECs showed this capsule interdigitating with internal vascular elements at 
6h; however, neither the FOS, nor the silicone showed endothelial cords within the 
implant interior at the 6h time point. By 12h, the SPECs displayed larger vessel-like 
bands composed of smaller cords penetrating through the implants, some of which 
bisected the implants (Figure 3.14). By 24h, many small lumen-like structures were 
present at the periphery of the implant connecting with the thicker endothelial capsules 
(Figure 3.14).  
 
Mural Cell Involvement  
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Mural cells improve vessel stability and reduce vessel turnover. They are recruited later 
in the vascularization pipeline, and stabilize vessels by forming connections with the 
endothelial cells toward the periphery of the vessels. At the 6 hour time point, there was 
very low mural cell involvement. However, by 12 hours there was a significant increase 
in mural cell recruitment indicated by the alpha-smooth muscle actin stain (yellow) in 
Figure 3.15.  
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Lumen Formation Within Implants 
Implanted cells were labeled with CellTracker Blue to distinguish them from the host. 
Cd31+structures (red) with apparent lumens are visible within implanted SPEC cells 
labeled with Cell Tracker (Blue) at 12 hrs post-implantation (Figure 3.16). These lumens 
were not present in the FOS or the silicone implants. 
 
Contributions to the Formed Vascular Networks 
Monoclonal anti-human CD31 antibody stain (red) and polyclonal anti-vWF 
antibody stain (green) were used to distinguish implant-derived networks from the host to 
determine the contributions of each to the vasculature seen (Figure 3.17). Host-derived 
vascular networks only stain for anti-vWF, while implant-provided vasculature is tagged 
by a colocalization resulting in a yellow label. The internal vasculature of the SPECs was 
largely implant derived, as indicated by the monoclonal human CD31 stain (Figure 
3.17A). By contrast, the endothelial capsule components in the SPEC and FOS only 
 99 
express polyclonal vWF, which labels both rat and human endothelial cells, indicating 
derivation from the rat hosts. Vessels in control sections of muscle without a surgical 
pocket similarly solely express vWF in their lumens (Figure 3.17B). Host-derived 
vascular networks only stain for anti-vWF stain and are visible at the external capsule 
surrounding the SPECs and in vessels distal to the implant site in the opposite host hind 
limb muscle (Figure 3.17C). 
 
Additionally, at 12-hours post-implantation, penetrating host-derived cords within 
the SPECs colocalized with the implant-derived components, indicated by cell tracker 
(blue) (Figure 3.18), indicating implant contribution to these endothelial structures. 
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Invading von Willebrand factor+ endothelial branches from the endothelial capsule 
inosculate with cell tracker positive endothelial cords (magenta) indicating both host and 
implant contribution to SPEC vascular network. 
 
Assessment of Long-term SPEC Implants (72 hours) 
Implanted constructs show early signs of anastomosis in a rat hind limb muscle. Within 3 
days, there was evidence of red blood cell perfusion in the implants with vascular 
structures that persisted out to 2 weeks (25).  The SPECs were implanted in hind limb 
defects, and excitingly by three days post-implantation neighboring satellite cells had 
been activated and were migrating towards the muscle defect site (Figure 3.19). 
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Applications of the SPEC Technology 
To investigate the potential for creating tissue-specific SPECs that are function as the 
tissue they are designed to be, Rhett, JM, et. al. incorporated islet cells to see if a 
prevascularized bioartificial pancreas could be created (28). Immunoconfocal microscopy 
images demonstrated the islet-containing constructs expressed insulin and retained the 
microvascular network seen in constructs without islets (Figure 3.20). Note the dense, 
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web-like pattern of endothelial cells in both constructs, indicating a robust vascular 
network. Importantly, the vascular network surrounds the embedded islets. These results 
indicate that the prevascularized bioartificial pancreas is a potential tool for improving 
long-term survival of implanted islet cells in vivo.  
 
As another application, we investigated the possibility of creating prevascularized renal 
tissue. Murine kidneys were micro-dissected and isolated for living corticomedullary 
renal segments (27). These segments were capable of rapid incorporation into the SPEC 
and form intact structures (Figure 3.21A). The constructs retained their prevascularized 
network shown by labeling with von Willebrand Factor for endothelial cells (Figure 
3.21E). However, unlike in the bioartificial pancreas, the prevascular network did not 
appear to invade the renal cellular material. Renal epithelial cells were labeled with 
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Cytokeratin-18 (green, Figure 3.21B). The constructs were incubated with FITC-labeled 
albumin (gray in Figure 3.21C) to test in vitro renal functionality. While there was 
resident albumin found away from the segments of embedded renal tissue, there are “hot 
spots” in the area of the renal tubular epithelial cells, which are known to take up albumin 
that traverses intra-luminally. Therefore, there was successful albumin reuptake in the 
renal segment SPEC construct.  
 
Scalability of the SPEC Technology 
The most important part of developing cellular technologies for tissue engineering, is the 
feasibility of scaling these constructs to physiologically-relevant sized tissues. Here, we 
have demonstrated the SPEC can be scaled up into larger, more complex geometries, and 
the use of the bioprinter, described in chapter 2, to fabricate these constructs could allow 
the creation of much larger and even more complex constructs, including patient-image 
derived implants.   
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Additionally, in preliminary work investigating the effects of perfusion on SPECs during 
their formation in vitro we found that the SPECs were able to readily fuse together to 
form larger constructs (Figure 3.23), which retained their vascular networks (CD31, red) 
and extracellular matrix components. This offers another potential technique for 
expanding this technology to the much-desired larger implants required for tackling the 
organ deficiency crisis. 
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3.6 DISCUSSION  
 
The timeline of vascular events (Figure 3.2) immediately following implantation 
of prevascular tissue is critical to evaluating the success of implant technology. The 
observation windows selected in this study were designed to dissect the components of 
endothelial organization, cord sprouting, anastomosis, network remodeling, lumen 
formation and, ultimately, vessel maturation that occurred early in the in vitro 
development of our implant and shortly following implantation. The 6-12h post-
implantation window is particularly important as it contains the time points associated 
with a peak in markers of hypoxic stress found within autologous full-thickness muscle 
flap transplants in prior studies by our laboratory (9).  
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In vitro SPEC development was consistent with non-random organization of a 
proangiogenic vascular network 
The endothelial cord formation within the SPECs is a non-random process, with 
the initial dispersed endothelial cells coalescing into cords throughout the 3-day 
incubation period. This migration stands contrary to the popular theory of cellular 
behavior termed the differential adhesion hypothesis (32). If the rearrangement was 
entirely driven by passive cell adhesion behavior rather than active vascular development 
processes, a single interface between endothelial cells within the core and fibroblasts on 
the periphery would be observed. This behavior would optimize interfacial energy based 
on cell-type specific expression of adhesion molecules such as cadherins (33). Further 
evidence of active vessel formation within the implant is provided by western blot data, 
through expression of vascular markers such as VEGFR2, VE-cadherin, and vWF.  Dll4 
expression in implants is consistent with angiogenic and anastomotic potential of 
endothelial cells as reported in literature (Figure 3.12; 34-35).  
Early 6hr post-implantation period demonstrates rapidity of endothelial capsule 
formation around implants, and rapid inosculation of scaffold-free prevascular 
constructs to host 
One of the major goals of vascular tissue engineering is near instantaneous 
perfusion of well-organized cords either by spontaneous in vivo inosculation or surgical 
anastomosis (1). While these constructs were not well perfused during the 24h 
observation time, endothelial structures extended continuously from the host to the 
interior of the SPEC implants within 6h, indicating rapid mobilization of endothelial cells 
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to and from the implant. Notably, the SPEC internal structures are derived from human 
endothelial cells (Figure 3.17), suggesting that this anastomotic network contains, at least 
in part, the preformed primitive network that was developed in vitro.  
Additionally, the microvessel vascular area of the SPECs 6h post-implantation is 
26±5% which is comparable to the vascular density of the implant prior to implantation 
and only approximately 1.2-fold lower than the average microvessel vascular area 
fraction throughout the 24h time point (Figure 3.13). The filamentous net-like primordial 
form of the network prior to implantation is preserved at 6h post-implantation, with a 
high branch point density of approximately 1.2x105 per mm2 implant tissue, resembling 
the pre-implantation average branching density of 1.12x105 per mm2. The FOS, on the 
other hand, show a significantly lower presence of branching endothelial structures 
within the implant stroma, with most of the 8 ± 3% microvessel area confined to the 
external capsule. As such, the fraction of the vascular area that includes internally 
penetrating tubules in the SPEC is 4.7-fold higher than the fraction within fibroblast-only 
spheroids.  
The 6 to 12-hour window shows increase in microvessel area in fibroblast only 
spheroids and silicone implants but not in SPECs; SPECs show remodeling and fusion 
of existing branches 
The 6-12-hour window is a period of remodeling in both the SPEC and FOS 
implant models. Notably, the band of host-derived endothelial structures around the 
implant appear to thicken with a small but significant increase of internally penetrating 
branches within some of the FOS. However, the mean microvessel area of the fibroblast 
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spheroids, including the capsular components, remains 3.2-fold lower than the SPEC 
implants and comparable to that of the silicone implants (Figure 3.13). In other words, 
the lack of an existing internal endothelial network in the FOS results in a 12-hour 
latency in vascular development of these implants compared to SPECs. The SPECs, on 
the other hand, maintain a nearly constant mean vascular area; however, there is a 1.5-
fold decrease in junctions within the implant and a 2-fold decrease in junctions within the 
endothelial capsule. This may be attributed to increased condensation of endothelial 
branches to larger structures, an example of which is seen in (Figure 3.14), where a 
denser band of endothelial structures appears to pass through the center of the implant 
and lumen like structures begin to appear within the SPEC implant cross sections.  This 
cohesion of existing endothelial cords to form larger multicellular structures is most 
consistent with formation of the early vascular tree during embryological vasculogenesis 
(36).  
Parity between SPEC and FOS angiogenic development by the 24-hour timepoint 
By 24h, SPECs and FOS begin to resemble each other in terms of endothelial 
organization and mean vascular area, with a greater preponderance of penetrating 
endothelial cords in the fibroblast- only spheroids than at previous time points. The 
advantage in anastomosis provided by the SPECs, thus, seems to lessen at the 24h time 
point, as cords from the peripheral endothelial capsule appear to reach the center of the 
FOS. This rapid invasion of vessels in a previously avascular space is itself a surprising 
finding. Vascular network can invade on its own as a part of foreign body response, but 
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the process has been cited to take a few days to a week (1). The presence of a branching 
vascular architecture, however, still seems largely limited to the SPECs.  
Evidence of maturation of SPECs at 12-24-hour without perfusion 
In angiogenesis, maturation of vessels follows anastomosis and usually occurs 
concurrent with perfusion of vascular networks (37). However, in the absence of 
consistent perfusion, the SPECs show some indication of vessel maturation. Smooth-
muscle actin presenting cells, representing mural, stabilizing cells such as pericytes 
around capillaries, or smooth muscle cells around larger arterioles and arteries, are 
recruited in the latter stages of angiogenesis, involving a careful interplay between 
basolateral elements of endothelial cells such as Tie-2, macrophages, and pericytes.[38, 39] 
The SPECs, which present with an apparently disorganized SMA+ cells at the early 6hr 
time points show SMA+ cells more fully organized around lumen like structures in the 
SPEC at the 12 and 24 hour timepoints (Figure 3.15). 
Conclusion 
The SPECs retain a set of properties that have inherent therapeutic value when 
incorporated into replacement tissue technologies. SPEC spheroids can readily fuse to 
form larger spheroids in unconstrained nonadherent conditions and can reshape their 
cytoskeletal structures to assume patterns dictated by linear confinements such as agarose 
mold.[26] This scalability and shapeable nature, coupled with the primary cord networks 
of the SPECs makes them ideal analogues to a vascular stroma or artificial vascular bed 
that is inherent to the function of most tissues. The SPECs readily incorporate renal 
segments[27] and pancreatic islet cells[28], paving the way for rapidly vascularizable 
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artificial renal grafts and bioratifical pancreas. The incorporation of these other cell types 
leads to the creation of tissue-specific implants, and could be extended to a multitude of 
other tissue-types, as the SPEC serves as the foundation building block of most functional 
tissues.  
As past studies have reported inosculation of prevascular implants at 2-5 days[40], 
vascularization dynamics in literature have not focused on early time points preceding a 
few days following implantation. Our study reveals that an earlier observation window 
informs us on the relative rapidity of endothelialization around cellular constructs and 
reveals that the crucial advantages to a prevascular network might be best seen within 6 
to 12 hours of implantation. By this period, the groundwork for a vascular pedicle feeding 
the implants has already been laid, with evidence of reorganization towards a more 
mature host-implant vascular network. Vascular tissue engineering strategies that proceed 
from this point should promote lumen formation and patency of the existing vascular 
architecture. 
Unmet Challenges of the SPEC Technology 
When implanted SPECs and FOS were examined for cell death at 6-hours and 24-
hours post-implantation, it was evident that the prevascular network in the SPEC did not 
alter the viability of implanted cells, as indicated by Tdt dUtp Nick-End Labeling Assay 
(TUNEL; green in Figure 3.24A) There was a significant increase in TUNEL+ cells 
between the 6 hour and 24 hour time points in both the SPEC and FOS implants 
compared to the surrounding rat host muscle (Figure 3.24B).  
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Additionally, while these implants get thoroughly perfused by 72-hours (Figure 
3.19A-C), there was inconsistent red blood cell presence within the 24-hour window we 
were examining (Figure 3.25).  
 
The upregulation of DLL4-expression in SPECS at day 2 is consistent with 
increased vascularization of the implant; in contrast, the comparative downregulation at 
day 3 of incubation, coinciding with when the implant finishes resolving into a solid 
structure, is consistent with quiescence of the prevascular networks. This period of 
quiescence may contribute to the latency between anastomosis and in vivo tubulogenesis. 
While ideally anastomosis of prevascular implants should only involve inosculation of 
externally located cords to the nearby host vasculature, the need to ramp up the 
angiogenic machinery of the construct cells might delay further morphogenesis of these 
tubes and delay perfusion through the resulting networks. Therefore, further investigation 
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into how to drive the SPEC further down the vascularization pipeline should be done to 
see if these challenges can be met. 
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CHAPTER FOUR 
THE ANGIOGENIC POTENTIAL OF SCAFFOLD-FREE PREVASCULARIZED 
ENDOTHELIAL-FIBROBLAST CONSTRUCTS 
Vasculature is required for tissue maintenance and regeneration in vivo. During 
normal tissue development, new vasculature is formed through vasculogenesis and 
angiogenesis. These processes are highly dynamic and regulated at multiple levels, 
including transcriptional hierarchies and the interactions of proteins, as well as signal 
inputs from the extracellular environment (1). In previous work, the Scaffold-free 
Prevascularized Endothelial-fibroblast Construct (SPEC) was shown to organize into 
vascular networks with distinct directional orientations that reflect self-assembly 
mediated tension, and was later shown to quickly anastomose with the host and promote 
vascularization upon implantation (2-4). While these cellular constructs have exhibited 
successful integration with the host vasculature, they have not reached the phase of 
tubulogenesis in vitro. To overcome the unmet challenges of the SPEC seen from our in 
vivo studies, we wanted to investigate ways to accelerate the SPEC along the 
vascularization pipeline in vitro (Figure 4.1). Specifically, we wanted to investigate 
methods for inducing lumen formation, and subsequent tubulogenesis, in the SPEC pre-
implantation. The ability to drive the SPEC further down the vascularization pipeline in 
vitro should improve its engraftment in vivo.  
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In recent years there has been a focus on understanding the process of vascular 
morphogenesis, and the mechanisms by which endothelial cells form tube networks with 
defined lumens (5). There is a distinct difference between the processes of lumen 
formation and tubulogenesis. Lumen formation is a local event that involves a small 
number of cells opening up a space between them, while tubulogenesis is the formation 
of a continuous lumen that spans the entire length of a vessel (6). The formation of these 
contiguous tubes via tubulogenesis is required for subsequent blood flow, and for tissue 
growth and viability.  
4.1 MECHANISM FOR TUBULOGENESIS IN VIVO: CORD HOLLOWING 
A proposed mechanism of tubulogenesis in vivo occurs via cord hollowing (6; 
Figure 4.2). Prior to lumen morphogenesis, blood vessels consist of coalesced cords of 
endothelial cells that lack apicobasal polarity. Luminal space is generated extracellularly 
between endothelial cells as they remain tethered peripherally. A possible mechanism for 
creating extracellular space between endothelial cells is the clearance of adhesions at the 
cord center. Clearance at the cord center can occur either by de-adhesion at the 
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apical/luminal membrane, and/or by redistribution of junctional molecules away from the 
cord center. Finally, luminal expansion occurs as a result of adhesion junction 
rearrangements until a single lumen spans the entire vessel.  
 
Adherens junctions provide strong cell-cell contacts mediated by the cadherin-
catenin complex and its interaction with the actin cytoskeleton (12). Cadherins are 
transmembrane glycoproteins that regulate calcium-dependent cell-cell junctions (11). 
Cadherins have important roles in establishing cell growth, migration, and polarity, as 
well as regulating tissue morphology and cell differentiation (9,11). Adherens junctions 
located at homotypic endothelial cell-cell contacts regulate endothelial cord permeability, 
and play an essential role in cord hollowing (8). These junctions are involved in the 
activation of many subsequent signaling cascades depending on the complexes formed.  
There are two primary cadherins expressed in the endothelium: Vascular 
endothelial cadherin (VE-Cadherin) and Neural cadherin (N-Cadherin). These adherens 
junctions have distinct functions in vascular maintenance. VE-Cadherin is the principal 
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endothelial-specific adherens junction molecule present in all vascular beds, and is 
essential for vascular morphogenesis (9). Its expression in endothelial cells is localized to 
homotypic cell-cell contacts, while N-cadherin is distributed throughout the entire cell 
membrane (11). This dispersion of N-cadherin to extra-junctional regions of the 
endothelial cell is regulated by VE-cadherin expression, and is proposed to be involved in 
vessel stabilization that occurs through interactions between endothelial and mural cells, 
such as pericytes and vascular smooth muscle cells, which helps stabilize vessels by 
anchoring the endothelium (9,11).  
Catenin recruitment to adherens junctions, specifically, the p120-catenin regulates 
cadherin turnover by regulating their entry into the degradation endocytic pathway (13). 
N-cadherin controls the levels and cellular distributions of p120-catenin in human 
endothelial cells, and thereby regulates VE-cadherin. Luo, et. al. did studies in Human 
umbilical vascular endothelial cells (HUVEC) and showed that a knockdown of N-
cadherin resulted in loss of VE-cadherin in endothelial cell-cell junctions, and that levels 
of junctional and non-junctional p120-catenin were significantly reduced (12). Therefore, 
both of these cadherins play critical roles in vasculogenesis and tubulogenesis by 
modulating adherens junctional components, and subsequent endothelial cell behavior.  
In response to angiogenic stimuli in vivo, endothelial cells undergo dynamic 
rearrangements of cell-cell junctions, while simultaneous maintaining their barrier 
function (8). This coordinated response is dominantly regulated by the adhesion 
molecules located at intercellular junctions. Specifically, Vascular Endothelial Growth 
Factor-A signaling is of interest for inducing lumen formation, and subsequent 
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tubulogenesis, in the SPEC because it regulates the levels of VE-cadherin at endothelial 
cell-cell junctions (7,8,10).  
 
4.2 Vascular Endothelial Growth Factor-A (VEGFA) Signaling 
Vascular Endothelial Growth Factor-A (VEGFA) is the most critical regulator of 
vasculogenesis and angiogenesis (7,8,10,15). VEGFA signaling mediates immediate 
responses, like vascular permeability, and long-term responses, such as endothelial cell 
survival, migration, and proliferation (10). Reduced production of VEGFA results in 
decreased angiogenesis, and is thought to contribute to impaired tissue repair. VEGFA 
and their receptors are critical regulators of new vessel development and the remodeling 
of existing ones (10). Blood vessel homeostasis is regulated by VEGFA, which in turn 
controls endothelial cell functions within the vessels.  
There are three receptors, VEGFR1, VEGFR2, and VEGFR3, that VEGFA can 
interact with. These receptors are regulated on numerous levels: the receptor expression 
levels, availability and affinity for binding to its different ligands, the presence of co-
receptors, the rate of cellular uptake, and extent of degradation and speed of recycling 
(10). VEGFR2 is the major signaling receptor in vascular endothelial cells, and is the 
main transducer of VEGFA effects on these cells differentiation, proliferation, migration, 
and formation of the vascular tube (10). VEGFR1 is expressed by monocytes and 
macrophages, and is not required for endothelial cell functions. VEGFR1 actually binds 
to VEGFA with a ten-fold higher affinity than VEGFR2, however it has poor kinase 
activity, and may act as a negative regulator of VEGFR2 by capturing VEGFA in order to 
spatially regulate VEGFR2 signaling and the formation of angiogenic sprouts (10). 
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VEGFR1 is majorly involved in regulating monocyte migration during inflammation. 
VEGFR3 is expressed by lymphatic endothelial cells and does not play a major role in 
tube-formation, in vivo (10).  
Of specific interest to us, VEGFR2 regulates VE-cadherin expression at 
intercellular junctions through VEGFA-VEGFR2-activated SRC signaling. Upon 
VEGFA-VEGFR2 binding, the receptor gets dimerized and then stabilized through 
interactions between membrane-proximal Ig-like domains, which allows 
trans/autophosphorylation of intracellular tyrosine residues. Specifically, the Y951 
residue, located in the kinase inert domain of the VEGFR2 receptor, gets phosphorylated, 
which binds to the SH2 of Tsad that in turn recruits and binds to the SH3 domain of Src, 
activating Src (Figure 4.3). Src activation is dependent on the phosphorylation of residue 
Y951, and regulates vascular permeability, cell-matrix components, and cell adhesion 
(10). The activated Src phosphorylates VE-cadherin at the Y658 residue of the 
cytoplasmic domain, which disrupts the binding of p120-catenin (13). This dissociation 
of p120-catenin results in VE-cadherin endocytosis and results in opening paracellular 
junctions and increases vascular permeability (8,13).  
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4.3 Sphingosine-1-Phosphate (S1P) Signaling 
Sphingosine-1-phosphate (S1P) is a bioactive lipid that stimulates both 
endothelial cells and fibroblasts. In vitro, Sphingosine-1-Phosphate (S1P) stimulates 
endothelial cell proliferation and survival, migration, capillary-like tube formation, and 
regulates the endothelial barrier permeability (14,15). In vivo, S1P binds to its receptor 
(S1P1) on endothelial cells to stimulate angiogenesis, and promotes the coverage of 
nascent vessels with mural cells for stabilization. S1P has also been reported to be 
involved in the stabilization of N-cadherin-mediated endothelial cell-mural cell 
interactions (12). S1P has been indicated as a key player in stabilizing N-cadherin-
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mediated endothelial cell-mural cell interactions both in vitro and in vivo (12). The 
maturating and barrier-protecting actions of S1P inhibit tissue edema and is predicted to 
produce synergistic therapeutic effects with other angiogenic factors, like VEGF (14,15).  
 
Due to the known pro-angiogenic effects of and potential crosstalk between these factors, 
exogenous administration of VEGF or S1P into the SPEC is predicted to accelerate in 
vitro angiogenesis. We hypothesize this dosing regimen will initiate lumen formation via 
cell-cell junctional rearrangements, which stimulates endothelial cell polarity and in turn 
recruits essential components of the tubulogenesis machinery to the site of lumen 
formation (7).  
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4.4 MATERIALS AND METHODS 
SPEC Formation 
The scaffold-free prevascularized endothelial-fibroblast constructs were created as 
described previously in chapter 3. Briefly, a high-density cell suspension of 1:4 human 
adipose microvascular endothelial cells (HAMEC, ScienCell) and normal human dermal 
fibroblasts (NHDF, Lonza) were seeded in a non-adherent agarose mold and cultured for 
three days. The rod-shaped SPEC with dimensions of 1 mm wide by 6 mm long, required 
9x105 total cells.  
Preparation of Vascular Endothelial Growth Factor-A and Sphingosine-1-Phosphate 
Vascular endothelial growth factor-A (VEGFA, R&D Systems Cat#293-VE-010) was 
prepared following manufacturer's instructions. Sphingosine-1-phosphate (Sigma-Aldrich 
Cat#S9666) was also prepared following the provided protocol. 
Dosing Regimen of SPECs with exogenous growth factors 
We decided to treat our SPECs at different time points during their formation, while they 
are undergoing the process of self-assembly. We seeded the cells in the non-adherent 
agarose molds at D.0. After 24 hours, we treated our constructs with VEGF as a D.1 
treatment by incorporating either VEGFA or S1P in the media. We harvested these 
constructs on D.3. As a second treatment group, we treated our SPECs 48 hours after 
seeding them into the molds, as a D.2 treatment. These constructs were also harvested on 
D.3. 
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Immunohistochemistry Analysis of SPECs 
Tissue sections were fixed in 4% paraformaldehyde solution for thirty minutes and 
subjected to hematoxylin and eosin staining, direct or indirect immunofluorescence 
labeling. Tissue sections were directly labeled with Hoescht 33342 nuclear stain 
(Molecular Probes, 1:10,000), and Alexa FluorTM phalloidin 488 (ThermoFisher 
Scientific A12379, 1:500) for F-actin. Selected sections were stained with primary 
antibodies to human CD31 (monoclonal antibody) (R&D Systems BBA7, 1:25). Primary 
antibodies were fluorescently tagged with the secondary antibodies Alexa FluorTM goat 
anti-mouse 488, goat anti-rabbit 546, goat anti-mouse 546, and goat anti-rabbit 633 
(ThermoFisher Scientific, A-11001,11035,11030,21070, 1:500). Sections were mounted 
on Colormark Plus microscope slides in Prolong Gold antifade reagent (Molecular probes 
P36934).  
Western Blot Analysis 
Treated SPECs were collected after their appropriate culture times in the 2% linear 
agarose molds as previously described. Samples were snap frozen, and mechanically 
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homogenized in RIPA lysis buffer with protease inhibitor cocktail. Samples were 
maintained in constant agitation for 2h at 4°C, centrifugated for 20 min at 16,000 g at 
4°C. Supernatant was stored in fresh tube at -20°C. PierceTM BCA Protein Assay kit 
(Thermofisher Scientific 23227) was used to estimate protein concentration for samples 
as per manufacturer’s instructions. Prior to gel electrophoresis, samples were diluted in 
RIPA buffer to attain 20 ug of protein in 20 uL solution, and further diluted 1:1 in 2x 
Laemmli Sample buffer to attain 40 uL loading volumes. Samples were loaded onto Any 
kDTM Mini-Protean® TGXTM Precast Protein Gels. Following protein separation and 
overnight transfer onto PVDF membranes, western blots were performed using 
antibodies towards GAPDH (loading control) (CalBioChem CB1001, 1:1000), VEGFR2 
(Abcam ab39256, 1:900), vWF (Abcam, ab6994, 1:500), DLL4 (Abcam ab7280, 
1:1000), Laminin (Abcam ab11575, 1:200), N-cadherin (Abcam ab98952, 1:200), 
VEGFA (Abcam ab46154, 1:200), Cdc42 (Abcam ab187643, 1:100), and Podocalyxin 
(PODXL, Abcam ab150358, 1:300). GAPDH was used as a loading control for all 
samples. 
4.5 RESULTS 
Immunohistochemistry Analysis of Treated SPECs 
VEGF-treated SPECs 
There were distinct differences between the untreated SPEC control, the D.1 VEGF-
treated SPEC, and the D.2 VEGF-treated SPEC. There was no lumen present at the 
interior of the untreated SPEC (Figure 4.6A). A singular, small central lumen was 
present in the D.1 VEGF-treated SPECs that was surrounded by organized endothelial 
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cells (CD31, red; Figure 4.6B). The D.2 VEGF-treated SPECs had a very large central 
lumen with densely packed endothelial cells surrounding the luminal area (Figure 4.6C). 
This could be attributed to the high pro-angiogenic potential of the SPEC at this time 
point during its normal formation in vitro, as indicated in the previous chapter by high 
DLL4 expression at this time point. Due to this, we believe the SPEC is most responsive 
to growth factor treatments at this time point during its formation. 
 
We also analyzed these constructs to see if there were endothelial cell-cell junction 
rearrangements in response to the VEGF treatment by looking at the expression and 
density of these networks (CD31, red; Figure 4.7). The untreated SPEC controls have 
endothelial networks that span across the entirety of the constructs, including the most 
central interior regions (Figure 4.7A). The VEGF-treated SPECs, however, have an 
obvious disruption of these networks at the interior of the constructs. This is indicative of 
VE-cadherin, the major endothelial cell-cell junction regulator, internalization, which 
follows the proposed process of cord hollowing.  
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S1P-treated SPECs 
In contrast to the single, central lumen found in both of the VEGF-treated SPECs, we 
found multiple smaller lumens present at the center region of the S1P-treated SPECs 
(Figure 4.8).  
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We also compared the expression of F-actin (indicated by phalloidin staining) of the S1P-
treated SPECs to the untreated SPEC control. We found that there was a much more 
dense F-actin network surrounding the luminal areas of the S1P-treated SPECs that was 
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not as dense as the untreated controls (Figure 4.9). This indicates the fibroblasts began 
secreting more extracellular matrix in response to the S1P treatment.  
 
Additionally, the F-actin fibers (green) and endothelial networks (red) in the S1P-treated 
SPEC appear more directionally aligned around the luminal area (Figure 4.9). 
Western Blot Analyses of VEGF-treated SPECs 
Podocalyxin (PODXL) is a marker of the early luminal surface. This molecule gets 
shuffled to the interior surface of the forming lumen. It is a charged molecule, and it’s 
presence at the interior luminal wall of newly-forming vessels is indicative of established 
polarity and the indictment of luminal expansion. Notably, we found that PODXL 
expression was upregulated in the VEGF-treated SPECs, indicating these constructs have 
established polarity and the cells at the interior are beginning to rearrange to permit 
luminal expansion through the entirety of the constructs (Figure 4.10). 
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In our analysis for vWF, we found that the VEGF-treated SPECs had a significant 
increase in expression, as compared to the untreated controls (Figure 4.11). This finding 
was surprising, and may be due to the densely packed endothelial cells surrounding the 
luminal region. The cells in this area serve to maintain the endothelial barrier integrity, 
while the interior cells undergo rearrangements to form a luminal space. Cdc42 is a small 
GTPase that induces vesicle formation and the formation of a luminal area. We found its 
expression was also increased in VEGF-treated SPECs. The expression of Cdc42 could 
indicate another mechanism participating in the formation of lumens in these treated 
constructs: vesicle fusion. Further investigation will be done in future work. We 
additionally found that N-cadherin expression was increased in only one of our treated 
constructs, which could be due to the disruption of VE-cadherin junctions, therefore cell-
cell adhesions rely on N-cadherin. This presence of N-cadherin could also be due to the 
incorporated fibroblasts, as this is not an endothelial-specific junctional molecule. 
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Finally, we analyzed the expression of laminin in our VEGF-treated SPECs. Laminin is 
an extracellular matrix component that is expressed on the abluminal walls of blood 
vessels. We found that it was uniformly expressed in all constructs, regardless of 
treatment. 
 
 133 
4.6 DISCUSSION 
We have looked at how to modify the capabilities of the SPEC to create different types of 
vascular patterns using growth factors. We were encouraged from our previous in vivo 
data that the SPEC had reached this later stage of vessel maturation in the pipeline by 72 
hours. With our recent in vitro data, incorporating the VEGFA and S1P during the 
formation of the SPEC constructs, and seeing network remodeling and lumen formation, 
we are excited to get these in vivo studies going in future work. We believe that SPECs 
treated with exogeneous growth factors in vitro are tailorable to application-specific 
demands, due to the obvious differences seen between the treatment groups. In our future 
work, we plan to analyze the S1P-treated SPECs using the same markers as described 
here to assess the VEGF-treated SPECs. We also want to investigate the possible 
synergistic effects of these two factors by treating SPECs with both of them during the 
culture period. Varying the ratio of endothelial:fibroblast cells used to create the SPEC 
constructs, could elicit different results from what is reported here, so we plan to 
investigate that possibility by including more endothelial cells at the time of seeding. 
Finally, we plan to implement the same animal model as described in chapter three to 
determine if they get perfused more quickly than the untreated SPECs once implanted. 
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CHAPTER FIVE 
THE SMART WOUND DRESSING 
From these promising findings described in the previous chapters, we started 
thinking about different applications we could apply these different technologies to. The 
Yost lab has been investigating wound healing for many years and through our 
collaboration with surgeons here at MUSC, we became interested in what goes wrong 
during this healing process, which results in a non-healing wound. We define these non-
healing wounds as chronic wounds. 
In the United States, chronic wounds account for more than $25 billion annually 
in health care expenses and affect over 6.5 million people, with 85% of these patients 
being 65 years and older (1-5, 34). Separate from direct healthcare expenses, an 
additional $15 billion is spent on wound care products, as well as another $12 billion on 
scar treatment, reaching almost $60 billion spent annually on chronic wound treatment. 
Additionally, these financial estimates do not include the morbidities facing these patients 
including lost work time, decreased productivity, disability payments, nor rehabilitation 
costs (34).   
5.1 NORMAL WOUND HEALING OF ACUTE WOUNDS 
Acute wounds affect over 11 million people in the United States every year 
(Singer). These wounds undergo a well-organized process of normal wound healing that 
leads to predictable tissue repair. Normal wound healing is a complex, highly regulated 
process that progresses through a cascade of events consisting of four temporally and 
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spatially regulated phases, including coagulation, inflammation, proliferation, and 
remodeling and scar formation (Demidova-Rice) (Figure 5.1).  
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Immediately after the injury occurs, platelets are activated and recruited to the 
injury site where they adhere to the damaged blood vessel. When the platelets adhere to 
the damaged vessel they release signaling factors, such as platelet-derived growth factor 
(PDGF) and transforming growth factors A1 and A2 (TGFA1,TGFA2), that initiate a 
blood-clotting cascade to prevent excess bleeding and the resultant clot provides 
temporary protection for the wounded area (Figure 5.1A). The released factors stimulate 
inflammatory cells, including leukocytes, neutrophils, and macrophages that then get 
recruited to the wounded area and begin clearing out foreign bodies and bacteria through 
the release of reactive oxygen species (D-R). This is the inflammatory phase of wound 
healing, which gets resolved upon the gradual apoptosis of these inflammatory cells over 
the span of a few days.  
As the inflammatory phase is being resolved, the proliferative phase of tissue 
repair is initiated (Figure 5.1B). The remaining inflammatory cells present at the 
wounded area begin to release growth factors, as well as migratory epidermal and dermal 
cells. The epidermal and dermal cells “act in an autocrine, paracrine, and juxtacrine 
fashion to induce and maintain cell proliferation while initiating cellular migration” to the 
site. All of these events are essential for forming granulation tissue and supporting 
epithelialization of the wound area (D-R). To sustain these incoming cells an angiogenic 
response is initiated to provide an adequate blood supply, which carries nutrients and 
oxygen, and allows for metabolite exchange. Angiogenesis in wound healing is initiated 
almost immediately after the injury occurs as the wound area becomes hypoxic. Initially, 
the activated platelets release proangiogenic growth factors including vascular 
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endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), and PDGF. After 
the inflammatory phase, the infiltrated cells also secrete these factors, which in turn 
regulate the angiogenic induction. Endothelial cells degrade their surrounding basement 
membranes, so they can “migrate toward the wound site where they proliferate, form new 
cell-cell contacts, and eventually new blood vessels” (D-R).  
Once the new blood vessels have been formed and normal blood supply is 
provided to the wounded area, epidermal and dermal cells migrate and proliferate within 
this area (Figure 5.1C). The wound epithelium gets restored by the epidermal cells, while 
the dermal cells, i.e. fibroblasts, secrete extracellular matrix to form granulation tissue, 
mainly consisting of collagen type I, that gets perfused with the previously formed 
vessels. As this occurs, a new provisional matrix consisting of collagen type III, fibrin, 
fibronectin, and hyaluronic acid gradually replaces this granulation tissue. The next, and 
final, phase of wound healing is wound contraction and matrix remodeling (Figure 
5.1C). Wound contraction is mediated by fibroblasts that respond to platelet-released 
TGFA, tissue tension, and matrix protein presentation. The fibroblasts generate actin-
containing stress fibers that induces contractile forces, which are transmitted to the 
surrounding extracellular matrix through focal adhesion complexes comprised of 
integrins. Additionally, the matrix is continuously reorganized through slow cycles of 
extracellular matrix generation and degradation, which occurs in a fibroblast-depdendent 
manner (D-R). Matrix degradation occurs via matrix metalloproteases (MMPs), which 
are critical regulators of the local matrix microenvironment and allow for cellular 
migration, proliferation, and angiogenic induction. Once the matrix has been sufficiently 
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remodeled, the fibroblasts begin to undergo apoptosis, which results in the formation of a 
relatively acellular fibrotic scar (Figure 5.1C). However, even when normal wound 
healing is successful, the resultant tissue can be disfigured and non-functional (35). For 
example, Figure 5.2 is of a patient treated at the Medical University of South Carolina 
Hospital with traditional therapies that left this patient with a non-functional tissue 
associated with reduced mobility and increased morbidity for this patient. 
 
5.2 THE CHRONIC WOUND ENVIRONMENT 
Chronic wounds are wounds that have failed to progress through the normal 
stages of wound healing (Figure 5.3). These wounds characteristically have an 
accumulation of metabolic waste products, proteins, and enzymes in the affected area, 
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leading to excess wound exudate. Chronic wound exudate inhibits fibroblast proliferation 
and contains proteases that degrade extracellular matrix and growth factors.  
 
Chronic wounds are also associated with high levels of pro-inflammatory 
cytokines, which have been shown to inhibit growth and induce morphological changes 
in normal skin fibroblasts, as well as arrest the healing process in the inflammatory state 
(4). Fibroblasts in chronic tissue appear larger and polygonal, tend to be non-responsive 
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to growth factor stimulation, and have reduced mobility and migration as compared to 
normal healing tissues. The irregularities of the predominant extracellular matrix-
producing cells lead to a compositional change in the structural environment, such as 
decreased production of laminin, fibronectin, collagen, as well as others, and inadequate 
matrix reorganization. Chronic inflammation can lead to endothelial cell dysfunction and 
impaired blood vessel regeneration. Bacteria are present on virtually all open wounds. 
Bacterial colonization occurs when the growth and death of microbes are kept in balance 
by the host immune system. When host defenses can no longer maintain this balance, the 
wound enters a non-healing, infected state. If the infection goes untreated, and turns 
systemic, the infected area may have to be amputated for patient survival. For example, 
the C. gas gangrene infection shown in Figure 5.3D of a patient treated at the Medical 
University of South Carolina hospital resulted in a lower right limb amputation due to the 
extent of the infection. From our literature search, we came up with a list of the major 
players contributing to impaired wound healing in these chronic wounds (Figure 5.4). 
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5.3 PRESSURE ULCERS 
Pressure ulcers, one of the most frequently observed chronic wounds in clinics, 
develop when an area of skin is placed under constant pressure for an extended period of 
time resulting in tissue ischemia, depletion of nutrients and oxygen supply to site, and 
eventually tissue necrosis (Osuala). When an area of skin is exposed to prolonged 
pressure, blood vessels within the distorted tissue are occluded and blood is unable to 
flow. While ischemia is the initiator of pressure ulcer formation, there are other 
underlying factors involved in the failure of these wounds to heal.  
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Pressure ulcers are classified as Stage 1 if the skin remains unbroken, but there is 
evident inflammation at the site with the area appearing red and warm (Figure 5.5A). 
Stage 2 pressure ulcers have partial-thickness loss of the epidermis, the outermost layer 
of the skin, and some of the dermis, however no slough is present (Figure 5.5B). Slough 
is soft, moist, avascular, dead tissue. Stage 3 ulcers are characterized by full-thickness 
skin loss, including epidermis and dermis, and necrosis of subcutaneous tissue (Figure 
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5.5C). Slough and necrotic tissue, as well as undermining and tunneling, may be visible, 
however, no underlying muscle, bone, or tendon is exposed (Figure 5.5E). Undermining 
is caused by erosion under the wound edges, resulting in a large wound with a small 
opening. Tunneling is a secondary wound caused by a high volume of pressure being 
forced upon many tissue layers, which can prompt the layers to become less voluminous 
than surrounding tissues, creaking a sinkhole-like effect in the skin. Pressure ulcers 
progress to Stage 4 when there is full-thickness skin loss including the epidermis, dermis, 
and subcutaneous tissue (Figure 5.5D). Underlying muscle, bone, and tendon may be 
visible, as well as slough, undermining, and tunneling.  
5.4 TRADITIONAL WOUND TREATMENT 
Wound dressing devices are a vital component in the treatment of chronic, non-
healing wounds. The traditional dressings predominantly used in clinics are shown in 
Figure 5.6. Plain dry gauze has historically been one of the most popular wound 
dressings. Gauzes have good absorptive properties, but can completely dehydrate the 
wound, which is detrimental to wound healing. They also tend to adhere to the wound 
surface and removal can be painful and traumatic. Due to their absorptive properties, they 
have limited ability to provide an effective barrier against bacterial invasion. 
Hydrocolloids are adhesive, occlusive (do not permit gas or fluid flow) dressings that 
absorb wound exudate to form a hydrophilic gel that helps maintain a moist healing 
environment. They provide protection against shear force at the skin surface. However, 
these dressings have risk of periwound maceration and, if the site gets too moist, may 
separate from the wound bed, requiring frequent dressing changes. Maceration occurs 
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when the healthy tissues surrounding the wound bed, i.e. the periwound, are exposed to 
excess moisture and begin to degrade, which can further impede wound healing, as well 
as lead to increased deterioration of the wound bed (31). Hydrogels are water-based 
materials that help maintain a moist environment. They can be applied and removed 
without causing pain or further trauma. Additionally, patients have reported pain relief 
with these dressings, likely due to their cooling effects. Foams are semi-occlusive 
dressings that provide thermal insulation and protect against shear. They are non-
adhesive, so there is no tissue injury or pain associated with dressing changes. However, 
foams have no protective barrier to prevent bacterial contamination and, like 
hydrocolloids, may promote development of excessive wound exudate requiring frequent 
dressing changes.  
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Traditional dressings fall short in addressing the three main issues that impede 
healing: preventing bacterial infection, ineffective inducement of cell migration and 
neovascularization, as well as maintenance of wound moisture balance and control of 
wound exudate. Additionally, standard of care techniques, for example wet-to-dry 
dressings, are labor intensive and can induce secondary injury and pain to the patient.  
5.5 MODERN WOUND TREATMENT 
Advanced wound dressings such as TriTech Silver and Apligraf®, a bi-layered 
cultured skin substitute, require numerous applications and have been unsuccessful in 
adequately closing chronic wounds (7,15,18-19). Tritec Silver® is a bi-layered device 
comprised of a Protective Layer and a Transfer Layer (Figure 5.7).  
 
The layer proximal to the wound is the Protective Layer, which supports two critical 
functions: regulating moisture and protecting surrounding healthy skin and underlying 
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tissues. The layer is designed with unidirectional fibers that only wick moisture vertically 
through the dressing and away from the wound bed. The top or transfer layer is composed 
of highly hydrophilic fiber that pulls exudate through the protection layer, away from the 
wound, and into a secondary dressing (i.e. gauze). This layer prevents accumulation of 
wound exudate. In addition, this dressing has a silver antimicrobial technology that 
releases silver ions when exposed to sodium-containing fluid, like wound exudate. While 
this product targets some of the contributors of wound healing, it has been met with 
limited success in case studies, and must be used in combination with other treatments, 
like compression therapy (15).  
Apligraf is a bi-layered skin substitute comprised of cells and collagen (Figure 
5.8). It is currently the only FDA-approved cell-based treatment for venous and diabetic 
ulcers (18).  
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The dermal layer combines a type I collagen matrix and human fibroblasts, which secrete 
additional matrix produces. The epidermal layer is formed from keratinocytes, which 
proliferate and differentiate to replicate the in vivo architecture. While Apligraf has 
shown promising results for the healing of acute wounds (Figure 5.8B), studies in 
chronic wounds found the graft did not persist long enough for therapeutic effects 
(18,19). This dressing also must be used with a secondary dressing, and is not a single-
application treatment option. 
5.6 THE SMART WOUND DRESSING (SWOD) 
When we started thinking about how to design a single device that can address all 
of the major players contributing to impaired wound healing, we reverted back to what 
the ancient Egyptians were doing in ~2000 B.C. They created combinatorial devices 
comprised of lint to address the excess wound exudate, animal grease to provide a 
hydrophobic barrier and protect the wound bed from the external environment, and 
honey, which has inherent antibacterial properties due to its osmolarity. In doing so, we 
realized there was no single material that could successfully provide all of these features 
(Figure 5.4), and began developing a multi-layered wound dressing, the Smart Wound 
Dressing (SWOD). The SWOD is a multi-component device made up of three separate 
layers that individually address different facets of the chronic wound environment 
(Figure 5.9). 
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The bottom layer of the SWOD, the anti-inflammatory layer, serves a dual 
function, first providing a provisional matrix to host cell migration, and second to 
regulate moisture balance in the wound bed. This layer was designed to address the 
deficiency in extracellular matrix proteins and provisional matrix in chronic wounds, and 
act as a scaffold for cell adherence and subsequent matrix deposition. Electrospun 
collagen was chosen because it has previously been reported to improve wound healing 
(27). The reaction electrospun collagen fibers are created using a novel technique 
developed in the Yost Lab at the Medical University of South Carolina. This technique 
produces a superior fibrous scaffold that is unique in its resistance to trypsin digestion, 
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and as produced, these fibers can donate or absorb water from the wound bed to maintain 
a moisture content equivalent to that found in healthy skin (22).  
The middle layer of the SWOD, the living component, has been incorporated to 
promote revascularization and angiogenesis at the wound site. This layer incorporates 
endothelial cells and fibroblasts to overcome the irregularities associated with these cell 
types in chronic wounds. These constructs have been engineered to contain a prevascular 
bed and supply reparative fibroblasts (21,28). This layer serves to provide cues to 
encourage migration and repopulation of the wound bed with viable host cells and 
promote revascularization to the site. Additionally, when implanted into the hind limb of 
a rat, the SPEC was shown to rapidly integrate with the surrounding host vasculature 
within 6 hours of implantation. Figure 5.10 shows that there is distinct overlap of the 
implanted cells, shown in Cell Tracker+ blue, coinciding with vasculature marker (vWF) 
that is labeling both the human implanted and the host rat vascular components.  
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Finally, the external side is composed of hydrophobic silver coated woven polyester 
and an internal membrane of 0.1𝜇m pore size, hydrophilic polytetrafluoroethylene (PTFE). 
The amphipathic nature of this layer creates a unidirectional flow of exudate out of the 
wound bed, thereby creating an appropriate environment that promotes regeneration, while 
preventing accumulation of excess wound exudate. In addition, the hydrophobic outer 
silver coating kills invading pathogens and provides an added layer of protection against 
infection (23). During the development of this layer many materials were investigated 
including regenerated cellulose, polysulfone, polycarbonate membranes, among others. 
Hydrophilic PTFE proved to be the best option for the SWOD, and has been widely used 
in medical applications, such as vascular grafts and surgical meshes (24-26). Its hydrophilic 
nature prevents protein binding, and subsequent cell or bacteria adherence, while 
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permitting the filtration of fluid. The combination of these product features specifically 
targets the issues encountered in treating and closing these difficult wounds. 
The Smart Wound Dressing (SWOD) is unique in its multifaceted approach which 
minimizes bioburden, while reviving normal wound healing mechanisms by increasing 
cellular migration, facilitating angiogenesis, and controlling moisture balance in the wound 
bed. The scientific premise of this project is that the overlapping functions of these layers 
combine to create a superior treatment by attenuating the multiple contributors to failed 
healing as compared to standard of care. The SWOD is a single application device, and its 
development will accelerate closure, shorten hospital stays, and reduce costs associated 
with chronic wounds. We believe that this combinatorial approach, which actively targets 
all of the contributors to impaired wound healing, will provide an exciting new option for 
the treatment of chronic wounds.  
5.7 METHODS 
Electrospinning Apparatus and Methods 
The electrospinning technology was developed and previously described by the Yost Lab 
at the Medical University of South Carolina (Figure 5.11; Patent Filed; 22).  
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Sputter-coating of Woven Polyester Membranes 
The top portion of the external layer comprises a woven polyester material with one side 
sputter-coated with silver using a Cressington 180 Auto/SE apparatus. In preliminary 
work we determined the optimal parameters for silver deposition across the entirety of 
the sample to be 30mA for 150 seconds for uniform coating. 
Total Silver-Loading Measurements 
Sputter-coated samples were analyzed for silver concentration using flame atomic 
absorption spectrometry (FAAS). Total ash from each membrane was measured and 
reported as a percentage of the starting weight of the material. Both the silver-coated 
woven polyester and the hydrophilic 0.1𝜇m PTFE membranes were imaged with 
scanning electron microscopy.  
Hydrophobicity of Silver-coated Woven Polyester 
The hydrophobicity of silver sputter-coated samples will be determined by contact angle 
measurements. Each side (A,B) of the polyester material was sputter-coated in silver for 
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one cycle (30mAmps for 150 seconds). The samples were placed on a level surface and a 12𝜇L drop of distilled water was deposited on top of it. Side-view images of the drops 
and a length reference scale were captured. The measurements required for analyzing the 
contact angles were taken and recorded in CellSens. Drop shape analysis was performed 
using the formula: Contact	Angle = 2tan%&( LCB1LH-./	MI?C) for quantifying the contact angles. 
Bulk Absorption 
The bulk absorption properties of the top layer of the SWOD was measured following the 
standard method (31). Silver-coated or plain woven polyester samples were cut into 22 
mm discs and the initial weight of each dressing was recorded. The samples were then be 
placed in a cup of simulated wound fluid (142mM	NaCl, 2.5mM	CaCl#	in	DI	H#O) and 
incubated at 37℃ in humidity for 30 minutes. Two marketed products, Gauze and CVS 
non-stick pads, were used as controls. The samples were removed from the solution and 
hung vertically for 30 seconds to remove any excess fluid. Finally, the sample was 
weighed to determine the final weight. Bulk absorption was calculated as: Bulk	Absorption = 	 NBFI4	"CB1LH%OFBHBI4	"CB1LHPECI	3Q	RI!S4C ( 1!"). This was performed in triplicate.  
Antimicrobial Properties of Silver-coated Woven Polyester Membrane 
Ubiquitous opportunistic microorganisms readily occupy the site of an open wound. The 
presence of these microorganisms above a specific bacterial load exacerbates the already 
unresolved inflammatory response. An antibacterial layer that preemptively excludes 
these organisms will improve our ability to accelerate closure. To assess the antimicrobial 
properties of our silver-coated woven polyester membrane, we performed a Kirby-Bauer 
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assay using three frequently seen bacteria in clinics, including MSSA, MRSA, and E. 
Coli.  
Cytotoxicity of SWOD Components 
The woven polyester membrane with and without a silver-coating were analyzed 
separately to assess cytotoxicity of the material. Samples were submerged in supplement-
free Endothelial Growth Medium (EGM) and incubated for 2, 8, or 14 days. Human 
adipose microvascular endothelial cells were cultured to confluence in a 96-well plate, 
and a 1:1 supernatant extract to EGM-2 volume (i.e. 100𝜇L supernatant and 100𝜇L 
EGM-2 per well) was added to the endothelial cells for 24 hours. At 24 hours, 
AlamarBlue was added at 10% total volume and incubated for 3 hours. During this 
incubation, the cells metabolize the blue non-fluorescent dye to red fluorescent resorufin. 
A microplate reader was used to measure fluorescence at an excitation length of 535 nm 
and emission of 590 nm. 
Moisture Content of Reaction Electrospun Collagen Fibers 
A piece of aluminum foil was weighed. Reaction electrospun collagen fibers were added 
to the aluminum foil, and excess water was removed using a Kim Wipe. The wet weights 
of the fibers were recorded, and the fibers were placed in an oven overnight. The dry 
weights of the collagen fibers were recorded, and the moisture content was determined 
from the amount of protein: Protein(%) = 8EG	"CB1LH"CH	"CB1LH × 100%.  
Formation of Scaffold-free Prevascularized Endothelial-fibroblast Constructs and 
Fibroblast-only Spheroids (FOS) 
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The scaffold-free prevascularized endothelial-fibroblast constructs were created as 
described previously in chapter 3. Briefly, a high-density cell suspension of 1:4 human 
adipose microvascular endothelial cells (HAMEC, ScienCell) and normal human dermal 
fibroblasts (NHDF, Lonza) were seeded in a non-adherent agarose mold and cultured for 
three days. The rod-shaped SPEC with dimensions of 1 mm wide by 6 mm long, required 
9x105 total cells. For controls, fibroblast-only spheroids (FOS) were formed from 9x105 
NHDF. 
Incorporation of Reaction Electrospun Collagen Fibers with SPEC  
Crosslinked collagen fibers were placed in the bottom of the SPEC agarose mold.  7.2e/ 
Normal Human Dermal Fibroblasts (NHDF) and 1.8e/ Human Adipose Microvascular 
Endothelial Cells (HAMEC) were seeded onto the fibers, and cultured for 3 days in order 
to validate that the SPEC will incorporate the collagen fibers when cultured together, and 
that the SPEC will retain its prevascular networks with surrounding matrix deposition.   
Drug Incorporation in Reaction Electrospun Collagen Fibers and Drug (JM-2) 
Release Kinetics 
The JM-2 peptide, denoted “P” in Figure 5.9, targets the microtubule-binding domain of 
connexin 43 hemichannels and was shown to prevent the release of cytoplasmic ATP into 
extracellular space, resulting in reduced inflammation and improved wound healing 
(Figure 5.12; Calder). We wanted to investigate the possibility of using the reaction 
electrospun collagen fibers as a drug delivery mechanism to improve wound healing in 
chronic wounds.  
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The 1% collagen fibers (wet) were UV-crosslinked with 6.3e/ TUD!". The JM-2 peptide was 
incorporated by dip coating 1.5 g crosslinked collagen fibers (wet) in buffer containing 180𝜇M of JM2 in a 12-well plate, and shaking for two hours at 4℃. The supernatant was 
removed and the fibers were placed in Eppendorf tubes, and stored in the -20℃ freezer. 1 
mL Dulbecco’s phosphate-buffered saline (+Ca, +Mg) was added to each well, and the 
fibers were incubated for 1 hour at 37℃. After 1 hour, the supernatant was removed and 
placed in Eppendorf tube, and stored in the -20℃ freezer. A fresh 1 mL PBS (+Ca, +Mg) 
was added. This was repeated at times 1, 2, 5, 17, 20, and 24 hours. The supernatants 
were then in -20℃ freezer until ready for use. We hypothesize that the UV-crosslinking 
will not impact drug release from the reaction electrospun collagen fibers, and that these 
fibers will serve as an adequate vehicle for drug delivery for our application.  
Invasion Assay 
A zone of exclusion was created in each well of a 12-well plate by placing a sterile 5 mm 
silicone disc on the bottom center of a culture well and seeding a monolayer of 5,000 
normal human dermal fibroblasts. After 3 days, and once the surrounding, perimeter 
fibroblasts had reached ~75% confluence, they were stained with Cell Tracker Deep Red 
following the kit instructions. The silicone discs were removed, and a SPEC was placed 
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in the center of the excluded area (Figure 5.13). An avascular fibroblast-only spheroid 
(FOS) was used as a control to determine the effects of having a prevascularized structure 
present on recruiting cell migration. The BioTek LionHeart FX Automated Live Cell 
Imaging Microscope was used to record cell migration over 7 days. This was performed 
in triplicate and analyzed using regression analysis for the time series data.  
 
Development of an in vivo Murine Pressure Wound Model 
For future in vivo studies to assess the functionality of the SWOD to heal pressure 
wounds, the Yost lab has created a murine pressure wound model by compressing full 
thickness tissue between a magnet and steel plate for 48 hours.  
5.8 RESULTS  
Reaction Electrospun Collagen Fibers 
Electrospinning, a technique developed at the Yost lab, is capable of recreating collagen 
fibers that closely resemble the in vivo niche (22; Figure 5.14). Here we have 
demonstrated that the collagen fibers produced with this technique retain the native 
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collagen molecular structure and mechanical properties that are tunable to the in vivo 
elastic modulus (Figure 5.14; 22). 
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Total Silver-Loading Measurements 
The total amount of silver deposited on the woven polyester membranes using 
Cressington 180 Auto/SE apparatus at 30 mAmp for 150 seconds was 0.12%. Figure 
5.15 shows scanning electron microscopy images of the silver-coated woven polyester 
and the hydrophilic 0.1µm PTFE membranes.  
 
Hydrophobicity of Silver-coated Woven Polyester 
The contact angles were measured for each side (n=8). The average contact angles were 133.37 ± 6.62° and 134.45± 4.48° for side A and B, respectively, with no significant 
difference between the two sides (Figure 5.16, P>0.5).  Both sides were sufficiently 
hydrophobic for our application, as indicated by contact angles greater than 90°. 
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Bulk Absorption 
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The bulk absorption of the standard 12-ply gauze and the CVS Non-stick pads were 
significantly higher than the woven polyester with and without silver-coating (Figure 
5.17). The woven polyester materials were still able to absorb 500 1!" of simulated wound 
fluid. While our materials absorbed less fluid than the marketed products, this may 
actually be advantageous because the other products can actually become to moist and 
induce maceration, the degradation of healthy surrounding tissues due to excess fluid 
exposure, which could actually increase the size of the wound and lead to more trauma.  
 
Antimicrobial Properties of Silver-coated Woven Polyester Membrane   
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To determine if the top layer is actively antimicrobial, we ran a bacterial colonization 
assay. We determined its bacterioscidal and had a zone of exclusion of 150 microns. We 
were very happy to see these results specifically with MRSA as this is an antibiotic-
resistant type of bacteria often seen in clinical settings. 
 
Cytotoxicity of SWOD Components 
Our analysis of cell toxicity indicated that the woven polyester was not toxic to 
endothelial cells (Figure 5.19). Importantly, the silver-coating did not hinder their 
viability, which was a concern during the development of this layer. Therefore, we 
believe we have the appropriate material, and have determined the appropriate silver-
loading, to act as an antibacterial, while permitting endothelial cell survival and 
functionality.  
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Moisture Content of Reaction Electrospun Collagen Fibers 
We theorize that it will also help maintain a moist wound environment by donating or 
absorbing water molecules to the wound surface. The moisture content of reaction 
electrospun collagen fibers was found to be 97.59 ± 0.33% and 97.50 ± 0.58% for 
0.75% and 1.5% collagen fibers, respectively (0.5<P<0.2, not significant; Figure 5.20). 
As produced, these fibers have an average moisture content of 97.54% with the water 
bound to the collagen. As there were no significant differences between these two 
collagen concentrations, we are not limited to a specific collagen concentration, and a 
variety of collagen fibers could be used for the treatment of these wounds. 
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Incorporation of Reaction Electrospun Collagen Fibers with SPEC  
SPECs were fixed and labeled with F-actin (Phalloidin, green), endothelial networks 
(CD-31, red), and nuclei (Hoescht, blue) to validate the formation of prevascular 
networks when reaction electrospun collagen fibers were incorporated during the 
incubation period (Figure 5.21).  The SPEC cultured with the collagen fibers retained the 
prevascular network, as well as adequate extracellular matrix production, indicating 
successful integration with one another. This data also suggests that the reaction 
electrospun collagen fibers will provide a scaffold for cell migration. 
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Drug Incorporation in Reaction Electrospun Collagen Fibers and Drug (JM-2) 
Release Kinetics 
Our Western Blot analysis of the JM-2 released from the reaction electrospun collagen 
fibers demonstrated that the method of incorporating the drug, UV-crosslinking, did not 
affect its release, and showed that the majority of the drug was released within the first 
two hours (Figure 5.22). Therefore, we believe the reaction electrospun collagen fibers 
serve as adequate vehicles for drug delivery. A multitude of other drugs, such as 
vancomycin, etc., and/or signaling factors, i.e. VEGF, PDGF, etc., could be incorporated 
into the RES collagen fibers. 
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Invasion Assay 
By 24-48 hours cells are actively migrating out of both the SPEC and FOS into the 
surrounding exclusion zone. By day 4 the surrounding healthy fibroblasts (indicated by 
yellow staining) had migrated across the zone of exclusion and integrated with both the 
SPEC and FOS constructs. By day 10 (not pictured) we had a monolayer of cells 
remaining. This was really exciting because it indicates the SPEC can re-establish cell 
communication and migration across wound area. Additionally, the SPEC provides 
endothelial cells, which can contribute to angiogenesis and new blood vessel formation, 
as well as fibroblasts that will secrete extracellular matrix and help stabilize newly 
formed vessels in the area. 
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SWOD Assembly 
To ensure all of the components of the SWOD can be successfully integrated and 
assembled into a single device, we have developed the prototype shown in Figure 5.24. 
We were able assemble all of the components, and in the future will be able to tailor the 
device depending on wound depth and the presence of tunneling and undermining in 
order to treat the entire wound area. 
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Development of an in vivo Murine Pressure Wound Model 
Figure 5.25A shows the successful creation of a pressure wound created by compressing 
full thickness tissue between an implanted steel plate and a magnet for 48 hours. The 
wound is approximately 8 mm on the long axis and 1.5 mm deep. There is an eschar in 
the wound that will be removed and the wound debrided prior to application of wound 
care technology. Figure 5.25B shows a hematoxylin and eosin stained section of the 
same wound in A, which highlights the loss of skin tissue, the necrotic muscle tissue and 
a fragment of the eschar. Figure 5.25C is an image of a full-thickness acute wound 
created using an 8mm biopsy punch, and Figure 5.25D is a hematoxylin and eosin-
stained section of the wound from C, showing the loss of tissue from the creation of the 
wound. We believe that these two models will serve as useful platforms for testing the 
SWOD in vivo.  
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5.9 DISCUSSION 
Described here is a novel wound healing device that successfully targets all facets 
contributing to the impaired wound healing observed in chronic wounds. We have 
demonstrated in in vitro studies that the woven polyester layer sputter-coated for 100s at 
150 mAmp, applying 0.12 wt% silver, is bactericidal to S. aureus MSSA and MRSA, E. 
coli, and E. faecalis and also non-toxic to cultured endothelial cells. Additionally, we 
have shown that the reaction electrospun collagen fibers have the appropriate moisture 
content for the wound area, and that they can serve as a provisional matrix for cells. The 
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reaction electrospun collagen fibers were able to be incorporated into the cellular 
component of the SWOD, the SPEC layer, during the three-day culture period, and were 
shown to be adequate vehicles for drug delivery, specifically JM-2, for this application. 
We were able to successfully assemble all of the components of the SWOD to create a 
prototype, and developed adequate animal models for testing this product in vivo for 
future studies. We believe the SWOD will perform superiorly to other marketed devices, 
and accelerate the time it takes chronic wounds to heal. Finally, the SWOD is novel in 
that it is a single-application device, which will reduce healthcare costs and morbidity 
associated with dressing changes seen with other devices. 
Future Possibilities of Generating a Patient-Specific SWOD 
Current treatments for chronic wounds, including pressure ulcers, are standard-
sized gauzes, films, and casts. There is no product that comes in patient-derived sizes, as 
even Apligraf® comes in standard sizes. During the treatment of these wounds, it is 
essential for a clinician to consistently check the wound progression, which is often done 
with imaging. 3D ultrasound (3D-US) has previously been used to image pressure ulcers 
as a prognostic indicator (41). These images can be used to produce volume-rendered 3D 
images for determination of the volume of a wound area. The MakerBot Replicator 2, a 
plastic 3D printer, can generate scaffolds with a resolution of 400𝜇m. With this 
technology, it is possible to take patient images and reproduce a 3D model. We have 
previously obtained CT images from a pediatric patient at MUSC suffering from 
craniosynostosis. Amira was used to convert the patient CT scans into CAD designs for 
use in surgical planning. The architecture of the models rendered were measured and 
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compared to the original scans to assess the resolution of this method. The plastic skulls 
were mimetic of the in vivo condition (Figure 5.26, Table 5.1).  
 
 
We can also incorporate these patient scans for use with the Palmetto Printer as 
discussed in chapter two to create patient-mimetic constructs. Figure 5.27 shows reaction 
electrospun collagen fibers serving as a substrate for cell printing, as could be used for 
creating the SWOD. 
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We have further expanded on methods for developing patient-specific dressings 
through the use of a novel imaging technique we have patented. The scanner is a multi-
camera system that uses structured light to calculate the dimensions and architectures of 
three-dimensional soft objects (Figure 5.28A). We are unique in having the capability of 
being able to recapitulate soft tissue areas with high fidelity, as demonstrated by this scan 
of an abdominal wound of an MUSC patient (Figure 5.28B). This technology can help us 
determine the depth of the wound, and how much collagen we would need, as well as the 
overall size of the SWOD dressing, allowing us to determine the number of SPEC 
constructs needed, as well as the other components. Additionally, these scans could be 
converted into bioprinter-compatible software and we could mimic a deficit as needed. 
This technology it is not limited to the creation of Smart Wound Dressings, but could also 
be used for many other tissue engineering applications. 
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In addition to developing patient-mimetic wound scaffolds with respect to 
structure, we have the technology to produce autologous cellular constructs (i.e. the 
SPEC component). In clinic, autologous cells could be harvested from the patient’s 
adipose tissue, and grown in culture. To generate patient-specific constructs, the wound 
scaffold could be created from patient images rendered into computer-aided design 
software and fabricated using a 3D bioprinter, specifically the Palmetto Printer, and 
subsequently seeded with cells (i.e. indirect bioprinting). The Palmetto Printer has three 
dispensers and is able to concurrently deposit heterogeneous materials and cell types. We 
have previously characterized the bioprinter for cell viability, reproducibility, and its 
ability to generate constructs in complex architectures.  
The most critical aspect of developing these novel technologies, especially those 
including cellular components, is the translational feasibility of actually being able to 
implement them in clinics. The following SWOD production timeline has been 
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developed, and has promising translatability due to the availability of the required cell 
types, as well as the short culture time periods. 
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